

B3

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization  
International Bureau**



(43) International Publication Date  
22 November 2001 (22.11.2001)

PCT

**(10) International Publication Number  
WO 01/88099 A1**

(51) International Patent Classification <sup>7</sup> :	C12N 5/06	(81) Designated States ( <i>national</i> ): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SI, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
(21) International Application Number:	PCT/GB00/01873	
(22) International Filing Date:	16 May 2000 (16.05.2000)	
(25) Filing Language:	English	
(26) Publication Language:	English	
(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application: US Filed on	PCT/GB99/03813 (CIP) Not furnished	(84) Designated States ( <i>regional</i> ): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CI, CG, CI, CM,

**(71) Applicant and**

(72) Inventor: DAVIES, Alison [GB/GB]; Bevos Farm, Tythegston, Bridgend, Mid Glamorgan CF32 0ND (GB).

(74) Agents: DZIEGLEWSKA, Hanna et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

卷之三

WO 01/88099 A1

**(54) Title: CELLS, CULTURE METHODS AND THEIR USES**

**(57) Abstract:** The present invention provides use of a host cell population obtained from a non-diseased host organism for the preparation of a cell composition for use in subsequent autologous transplantation therapy of said host organism.

Cells, Culture Methods and their Uses

- 5      The present invention relates to autologous transplantation therapy and in particular to the removal of samples of eukaryotic tissues or cells from a healthy host organism for subsequent transplantation to that host, after a temporal change to the host, for example  
10     when the need arises, e.g. a therapeutic need. The advantages are that cells held in suspended animation (ie. dormant cells) can be manipulated and/or revitalised at a future date when required eg. for therapy. Cell samples in a state of suspended animation  
15     can also be accumulated by performing several rounds of harvesting of primary samples from the same source organism(s) prior to the manipulation and/or revitalization.
- 20     The maintenance and replication of eukaryotic cells in culture has been practised for many years. Studies at the beginning of this century (Proc. Soc. Exp. Biol. Med. 4 (1907) 140; J. Exp. Med. 15 (1912) 516) have demonstrated that it is possible to remove animal or  
25     human tissue samples and maintain the cells therefrom in *in vitro* culture for various lengths of time depending upon the culture conditions. Most early culturing consisted of immersing animal tissue or cells in blood, or blood components such as serum. Blood or serum was  
30     the major component of the medium within which tissue/cell samples were cultured. However, as our knowledge of the *in vitro* requirements of cells has increased, the use of serum or blood components in cell/tissue culture medium has decreased to the extent where  
35     fully defined media are now available which provide all the nutrients and supplements necessary to maintain at least some cell types in culture (see e.g. Freshney's

- 2 -

Tissue Culture of Animal Cells, (Culture of Animal Cells: A Manual of Basic Technique, Wiley Liss, 1994)).

However, the maintenance of eukaryotic cells in culture  
5 for sustained periods has always been and remains  
fraught with difficulty. The major problem is that it  
is generally not possible to keep eukaryotic cells taken  
from multicellular organisms in primary culture for more  
than a few days to weeks. This is because cells in  
10 primary culture have a limited lifespan. In some  
instances, though, their maintenance can be prolonged  
indefinitely. For example, a single cell, or group of  
cells, can undergo genetic changes which enable it/them  
to maintain continuous cell replication in an *in vitro*  
15 culture environment. Such genetic changes usually  
involve mutations which activate cellular proto-  
oncogenes to become oncogenes, and/or mutations which  
restrict or negate the activity of tumour suppressor  
genes, leading to the loss of replication inhibition and  
20 to the development of cellular immortality (*Trends in  
Genetics* 9(1993)138). Our current understanding implies  
that tumour cells give rise to cancers not because of  
the sudden activation of immortalizing oncogenes, but  
because of mutations in genes which normally regulate  
25 the cell's ability to limit its own replication. These  
genetic events, which occur *in vivo* as well as *in vitro*,  
have led to the generation from multicellular organisms  
of eukaryotic cell lines that can be maintained in  
continuous culture (*Culture of Animal Cells: A Manual of  
30 Basic Technique*, Wiley Liss, 1994).

Although it is possible to maintain cell lines in  
culture, their ability to undergo continuous replication  
may make it disadvantageous or undesirable to do so. In  
35 order to save on resources, it would be better if it  
were possible to store cells until they were required  
for culture. Technologies permitting such storage have

- 3 -

been developed, with much information coming from studies with prokaryotic organisms.

Early work with prokaryotic organisms such as bacteria and viruses showed that it was possible to keep them in a state of dormancy for long periods of time without affecting their ability to survive and replicate once revived, or revitalised, from their state of dormancy. It was shown that prokaryotic organisms could be put into a state of dormancy (suspended animation) using a number of methods such as freezing, freeze-drying, drying or by placing them in various organic or inorganic solutions with or without subsequent freezing. The solutions include dimethylsulphoxide (DMSO), ethanol, ether, glycerol, phosphate buffered sodium chloride, and serum, or mixtures thereof, or with any other substance that can prolong shelf-life but is not confined to them.

Many, if not all, of the methods for placing or maintaining prokaryotic cells in a state of dormancy have also been applied to eukaryotic cells.

Maintaining cells in a culture environment enables manipulations to be performed on cells *in vitro*, and this advantage has led to the development of cell-based assays in diagnostic technology. Cell culturing, therefore, either prior to inducing dormancy or after cell revitalisation has been shown to have important applications for diagnostic medicine as well as basic science (Bone 22(1998)7; J Bone Min Res 13(1998)432).

In addition to medical diagnosis, cell culture methods have also been applied to medical therapies. For example, in cases where patients are suffering from leukaemia, one approach to alleviate the disease is to eradicate the patient's tumour cells by radiotherapy,

- 4 -

chemotherapy and/or surgery. However, radiotherapy and chemotherapy, which are seemingly the only practical treatments for diseases which are systemic and/or metastatic, may also destroy or substantially deplete  
5 the patient's normal, non-tumour haematopoietic cells. Consequently, it is standard practice to replace the patient's depleted normal cells with those from the bone marrow of a donor. The donor is often a close relative whose 'tissue-type' is similar to that of the patient,  
10 and the donor tissue is therefore less likely to be rejected by the patient (Adv Immunol 40(1987)379).

In addition to possible rejection of the grafted cells by the host, there is also the potential problem of  
15 graft versus host (GVH) disease. The vast majority of lymphocytes in a marrow donor sample are immature and unable to elicit a full-blown immune response without first undergoing a process of maturation. Maturation occurs when lymphocytes are processed via the thymus.  
20 If immature lymphocytes from the donor are processed through the new host's thymus they will accept the host as "self". However, it is inevitable that a proportion of the donor T-lymphocytes will have undergone maturation via the donor's thymus prior to  
25 transplantation, and, consequently, might regard the recipient as foreign. If so, the mature donor T-lymphocytes may attempt to attack the host's cells leading to GVH disease (Immunol Rev 157(1997)79).  
30 To reduce the possibility of the graft rejecting the host, the donor marrow samples can be trawled with, for example, antibodies which specifically recognise and bind to mature T-cells allowing for their removal or lysis prior to transplantation (Curr Op Oncol  
35 9(1997)131). It can be seen, therefore, that the *in vitro* culture of donor human cells and their manipulation prior to grafting is a recognized

- 5 -

methodology in transplantation therapy.

For the treatment of diseases such as leukaemias and lymphomas it is often more practical to provide donor marrow well before it is required for transplantation to the patient. In these instances, the donor marrow sample is made dormant e.g. by the addition of DMSO to the sample followed by freezing of the sample. The donor sample may be kept in a frozen state for, potentially, many years prior to its use for grafting, with little deterioration. Moreover, the donor cells may be manipulated, eg. the mature T-lymphocytes removed, either before or after freezing. The ability to store the marrow samples for long periods has enabled donor marrow banks to be set up to support treatment programmes for patients with various leukaemias and lymphomas (Bone Marrow Transpl 17(1996)197).

The recognition that it was mature T-lymphocytes in donor marrow that caused GVH disease, and the development of technologies to effectively remove them from donor marrow, has helped make significant advances in bone marrow allografting.

By way of definition, allograft means cells or tissue grafted or transplanted between different members of the same species; a xenograft is a transplant of tissue/cells between members of different species; and an autograft is a tissue/cell graft from self to self.

Prior to the scientific advances which made allografting feasible for the treatment of lymphoma and leukaemia, bone marrow transplantation was restricted to autografting (Stem Cells 13(Suppl 3)(1995)63). As defined above, autografting is where cells/tissue are removed from an individual, and grafted back to the same individual. Autografting remains commonplace, and is

- 6 -

- particularly relevant in the treatment of burns where skin is removed from undamaged regions of the body and grafted to help repair/regenerate the damaged skin areas (Burns 24(1998)46). Autografting is also common in
- 5 orthopaedic surgery where the patient's own bone is taken from eg. the pelvis, rib, or chin and used to augment/repair bone in another region of the body, eg. the face (J Oral Maxillo Surg 54(1996)420).
- 10 Autografting for the treatment of leukaemias and lymphomas has advantages and disadvantages. The key advantage to the patient is that there is no problem of rejection (either by the patient or by the graft) when cells/tissue from the patient are returned to the
- 15 patient. The main disadvantage, though, is that the grafted cells/tissue removed for subsequent grafting may contain diseased cells. The value of autografting, therefore, is dependent on the ability to obtain or produce donor tissue which is disease-free.
- 20 Leukaemias and lymphomas, by definition, are diseases affecting cells of the blood and the lymph, and the medical consensus is that seeding or infiltrating of diseased cells to bone marrow can occur irregularly, may
- 25 involve specific bone marrow sites, and/or happen late in the onset disease. Hence, the rationale for autografting leukaemia/lymphoma patients is that, once the patient has been treated by radiotherapy and/or chemotherapy to destroy tumour cells, it should be
- 30 possible to return their own, essentially disease-free, bone marrow.
- To further ensure that the autografted sample is essentially free of disease, it can be treated in a
- 35 number of ways. For example, it can be purged by separating/destroying residual tumour cells in the sample. A common purging method, for instance, is to

- 7 -

apply tumour cell-identifying antibodies to tag the tumour cells in the sample - the tumour cells can then be removed using cell-sorting technology such as fluorescence-activated cell sorting (Curr Op Hematol 5 4(1997) 423).

The value of autografting for the treatment of metastatic or systemic disease such as leukaemia and lymphoma remains questionable, though, since the donor 10 sample may still contain some element of the disease which cannot be completely purged with current technologies. The quality of the autograft will also depend on the status of the disease in the donor material eg. the type and aggressive nature of the cells 15 involved, the ability of diseased cells to seed the marrow, and the time from onset of the disease when the donor sample was taken. In essence then, the value of an autograft in such circumstances is empirical and will vary significantly between individual patients who 20 present with various symptoms of proliferative disease.

Advances in therapy continue to be made, and our greater understanding of disease processes helps us to modify and refocus our therapeutic approaches to alleviate 25 disease and suffering. Such understanding has been greatly advanced by technological improvements in the field of molecular biology. We are now in a position to follow the pathogenesis of diseases at a molecular level, and recognize the importance of an individual's 30 genetic make-up in predisposing them to certain diseases. For example, we are aware that some individuals, because of their genetic composition, are prone to cancers, e.g. leukaemias and vascular disorders such as heart disease. They may be also predisposed to 35 neurodegenerative diseases such as Alzheimer's disease and Huntington's chorea, as well as to endocrine and exocrine diseases such as diabetes and hypothyroidism,

- 8 -

and skeletal disorders such as age-related osteopaenia, osteoporosis, arthritis and periodontal disease.  
Through genetic testing, therefore, it is now possible to identify those individuals predisposed to  
5 debilitating diseases.

Furthermore, our knowledge of the body's immune system, and in particular the way in which it recognises and kills virally-infected and tumour cells, continues to advance. We now know that in order to elicit cell-mediated immunity, an offending cell (e.g. a virally-infected or tumour cell) must co-present an HLA class I restricted tumour or viral epitope with danger signals such as GM-CSF and/or TNF- $\alpha$ , so that the antigen-presenting cells (APC) of the immune system will express co-stimulatory signals such as B7 and IL-12 in conjunction with antigen to the interacting cytotoxic T-lymphocyte (CTL) population. The co-presentation leads to the production of clones of both activated and memory cells (for review see Nature Medicine Vaccine Supplement 4(1998)525). In the absence of these additional signals, HLA-I antigen-restricted T-cells which recognise offending cells are processed for destruction or desensitization (a bodily process presumably put into place to avoid the development of eg. autoimmune disease). The induction of such tolerance is because of either ignorance, anergy or physical deletion (Cold-Spring Harbour Symp Quant Biol 2(1989)807; Nature 342(1989)564; Cell 65(1991)305; Nature Med 4(1998)525).  
10 It is now clear that tumour cells do not automatically co-present danger and/or co-stimulatory signals. Hence, the spawning of a tumour may lead to eradication of the very cells that provide cell-mediated immunity against the tumour. A patient presenting with a cancer,  
15 20 25 30 35

leukaemia/lymphoma or sarcoma etc, therefore, may have already removed their innate ability to destroy the tumour, by default. However, if the required T-

- 9 -

lymphocytes, or a sample thereof, were removed from the patient prior to the onset of proliferative disease, the relevant T-cell population could now be returned to the patient, after the necessary co-stimulation of the T-cells, so as to alleviate disease. Co-stimulation may be provided at the same time as the cells are returned to the patient, or after they are returned through further treatment(s) of the patient, or without stimulation other than that naturally produced by the patient.

The present invention is based on our recognition of this possibility, namely the concept of removing cells or tissues from a healthy host organism for subsequent transplantation to that same host organism in a subsequent autologous (autogeneic) transplantation procedure, when the need or desire to do so arises. It is pointed out that the host organism may never receive the cells because no disease to be treated by this method ever occurs.

In one aspect, the present invention thus provides use of a host cell population obtained from a non-diseased host organism for the preparation of a cell composition for use in subsequent autologous transplantation therapy of said host organism.

Alternatively expressed, and in another aspect, the invention provides a method of autologous transplantation therapy, said method comprising transplanting a host organism with a cell composition prepared from a host cell population obtained from said host organism when non-diseased.

More particularly, this aspect of the invention provides a method of autologous transplantation therapy, said method comprising obtaining a population of host cells

- 10 -

from a non-diseased host organism; and preparing a cell composition from said host cell population for subsequent transplantation to said host organism.

5 A further aspect of the invention provides a cell composition comprising a host cell population obtained from a non-diseased host organism for use in subsequent autologous transplantation therapy of said host organism.

10 A still further aspect of the invention provides use of a host cell population obtained from a non-diseased host organism for subsequent autologous transplantation therapy of said host organism.

15 The host organism may be any eukaryotic organism, but preferably will be an animal, more preferably a mammal, and most preferably a human. Other representative host organisms include rats, mice, pigs, dogs, cats, sheep, horses and cattle.

The term "non-diseased" is used herein to describe a state in which the organism is healthy, ie. not suffering from any disease or disorder, or is not manifesting any symptoms of said disease or disorder ie. is asymptomatic or is in a pre-clinical condition. In particular, the host organism is not suffering from, or demonstrating symptoms of, the disease or disorder, which it is subsequently intended to treat by the transplantation procedure.

Furthermore, in certain embodiments of the invention, the host organism is preferably not predisposed to, or at risk from, any particular disease or disorder e.g. preferably not exhibiting any symptoms or manifestations predictive of a subsequent disease or disorder. Likewise, the host organism is preferably not suffering

- 11 -

from any injuries or damage which may give rise to an anticipated or expected condition. A major idea or concept behind the present invention is to harvest or collect the host cells from the host organism at a stage  
5 when there is no direct prediction, suggestion, or suspicion that a particular disorder or disease may develop, for use against a future possible or unpredicted event, or an event which may occur simply by chance, rather than an anticipated or suspected or  
10 predicted illness or condition.

Also included, is the removal of cells from a "non-diseased" region or area of the body of the host organism, even though other areas or regions of the body  
15 or cells or tissues of the body may be affected by a disease or disorder. What is required is that the cells removed are themselves healthy ie. "non-diseased" within the definition given above.

20 In preferred embodiments of the invention the cells are obtained from the host organism before any disease or disorder develops or manifests itself, and more preferably when the host organism is in general good health, and preferably not immunocompromised in any way.

25 Thus, it is particularly advantageous to harvest the cells from the host organism at a time when the organism has not previously exhibited symptoms of or presented with or been diagnosed as suffering from the disease or  
30 disorder which is subsequently to be treated, i.e. the host organism is not "in remission" e.g. not in a state of partial or full recovery from the disease to be treated.

35 Hence, by specifying in this aspect of the invention that the host organism "is not in remission from the disease or disorder to be treated by said therapy", the

- 12 -

autologous transplantation method as disclosed on page 26 lines 8-20 of WO 98/39427 is specifically excluded. It will be appreciated by those skilled in the art that the autologous transplantation as referred to in  
5 WO98/39427 as being concerned with harvesting of cells from a "healthy patient" refers in fact to the well-known technique of treating a "patient" who has made a temporary recovery from a previously diagnosed disease i.e. the "healthy patient" is in fact in a state of  
10 remission from the disease. Of course, the individual to be treated according to the invention may have suffered from other, unrelated diseases or disorders before the cells are harvested or they may be predisposed towards or have a genetic disease (e.g.  
15 Huntingdon's chorea) which does not develop or present symptoms until much later in life.

Advantageously, therefore, the host cells are obtained from host organisms when they are young, preferably in  
20 adolescence or early adulthood. In the case of humans, cell sampling at the ages of about 12 to 30, preferably 15 to 25 is preferred. Especially preferably, sampling is from the age of 16 or 17 upwards, for example in the age range 16 to 30, 17 to 30, or 18 to 30, or perhaps 18  
25 to 35 or 40. It is thus preferred that the cells be obtained when the host organism is mature, or reaching maturity, but before the processes of ageing or senescence have significantly set in. In particular, it is preferred and advantageous that the immune system of  
30 the host organism is mature or fully developed. However, the obtention of cells outside these ranges is encompassed, and cells may be obtained at any post-natal life stage e.g. from juvenile host organisms e.g. in mid-to late childhood, or even infants, or from older  
35 individuals, as long as they remain "non-diseased". Foetal host organisms are thus excluded from the present invention and sampling of foetal cells is not

- 13 -

encompassed.

In contrast to sampling umbilical blood for example, the advantages of the present invention are that taking 5 cells from post-natal or older hosts allows multiple samples to be collected, thereby increasing the opportunity of storing sufficient number of cells. In addition sampling from juvenile or older hosts overcomes the ethical requirements such as providing informed 10 consent.

Sampling from adolescent or adult host organisms is preferred since the sampled cells, from blood in particular, will contain a greater proportion of 15 valuable mature T-cells capable of recognising aberrant cell populations, such as cancer cells or virally-infected cells. Thus, when blood samples are used, it is advantageous that they are taken from an individual with a mature immune system (ie. not foetal or neo-natal). 20

The term "autologous" is used herein to mean that the transplantation is to the same organism (ie. the same individual) from which the host cells were removed. 25 Thus, autogeneic transplantation [self-to-self] or autografting is intended.

"Transplantation" refers to any procedure involving the introduction of cells to an organism. Thus, any form of 30 transplantation or grafting known in the art is encompassed.

"Transplantation therapy" refers to any procedure involving transplantation of cells. Both therapeutic 35 (e.g. curative or palliative, or symptom-relieving) and prophylactic (ie. preventative or protective) therapies are covered. Thus, the term "transplantation therapy"

- 14 -

encompasses the transplantation of cells to a host organism in need thereof, or in anticipated, expected or suspected need thereof, for any reason. Advantageously, the transplantation therapy is to treat or alleviate a disease or disorder which develops, or is threatened, subsequently, e.g. cancer or infection, or a degenerative condition (e.g. neuro-degenerative).

The host cells may be, or may comprise, any cells of the host organism, including both individual cells and cells comprised or contained in any tissues of the body, including both body fluids and solid tissues. The term "host organism" as used herein means the post-natal body, and does not include "waste" or "disposable" tissues which are not part of the body *per se*. Thus, the umbilical cord and placenta are not included. However, any part of the actual body of the host organism may be used as the source of the host cells. Representative cells thus include haemopoietic cells, e.g. blood cells, spleen cells, thymus cells or bone marrow cells; neural tissue cells (i.e. cells of the nervous system); liver cells; pancreatic cells; skin cells; hair cells; gut cells; marrow stromal cells which derive myoblasts, chondroblasts, adipocytes, osteoblasts, fibroblasts and their progenitors, or cells of any body organ or tissue. Preferred sites of removal of cells from the body include bone marrow, bone marrow stroma, neural tissues, internal organ tissues or dermal tissues. All cell types are encompassed, as are different stages of cell differentiation, including both undifferentiated, and partly or fully differentiated cells, e.g. stem, progenitor or precursor cells or fully differentiated cells.

Stem or progenitor cells are particularly included according to the invention, including both pluripotential stem cells and stem or progenitor cells

- 15 -

already committed to a particular path or paths of differentiation. Particular mention may be made of haemopoietic stem cells and neural stem cells, marrow stromal stem cells, gut stem cells, dermal stem cells  
5 and other epithelial stem cells.

A preferred cell type according to the invention is the lymphocyte, especially a T-lymphocyte (a T-cell) which may be obtained from any convenient source in the body,  
10 advantageously blood, bone marrow, thymus, lymph or spleen. Mature T-lymphocytes are particularly preferred.

Other preferred cell types and sources include  
15 osteoblasts, chondroblasts, chondrocytes, adipocytes and fibroblasts, which may be marrow stroma-derived.

Still other preferred cell types and sources include neuronal cell types (such as striatal, cortical,  
20 motoneuronal, dopaminergic, noradrenergic, serotonergic, cholinergic cells) from the brain and spinal cord, or glial cell types (such as oligodendrocytes, Schwann cells, astrocytes and micro-glia) from the central and peripheral nervous system.  
25

The disease or disorder which may be treated by the transplantation therapy may be any disease or disorder known to man. Thus any disease condition, illness, disorder or abnormality of the body is included.

30 Mention may be made, for example, of infections e.g. diseases arising from pathogenic activity e.g. bacterial, fungal or viral infections, or infections by any other organism e.g. a protozoa or other parasite; any malignant or pre-malignant condition; proliferative  
35 or hyper-proliferative conditions; or any disease or diseases arising or deriving from or associated with a functional or other disturbance or abnormality, in the

- 16 -

cells or tissues of the body, e.g. aberrant gene expression or cell or tissue damage (whether induced or caused by internal or external causes e.g. ageing, injury, trauma or infection etc.), or idiopathic 5 diseases (e.g. Parkinson's disease).

Advantageously, the present invention has particular utility in the therapy of chronic conditions (ie. chronic diseases or disorders).

10

Representative diseases or disorders thus include any cancer (whether of solid tissues of the body (e.g. prostate or mammary tumours), or of haemopoietic tissues or other individual cells, in particular leukaemias or 15 lymphomas), vascular disorders, neural disorders including in particular neuro-degenerative conditions, endocrine and exocrine diseases and skeletal disorders, as discussed above, or any condition associated with ageing or senescence. Particular mention may be made of 20 osteoporosis and osteoarthritis.

Therapy of cancer represents a preferred embodiment of the invention, and includes cancers of any cells or tissues of the body. The invention is not limited to 25 any one type of cancer (e.g. leukaemia, lymphoma, carcinoma or sarcoma), nor is it restricted to specific oncogenes or tumour-suppressor gene epitopes such as ras, myc, myb, fos, fas, retinoblastoma, p53 etc. or other tumour cell marker epitopes that are presented in 30 an HLA class I antigen restricted fashion. All cancers such as breast, stomach, colon, rectal, lung, liver, uterine, testicular, ovarian, prostate and brain tumours such as gliomas, astrocytomas and neuroblastomas, 35 sarcomas such as rhabdomyosarcomas and fibrosarcomas are included for the therapy by the present invention.

A further preferred embodiment of the invention is the

- 17 -

therapy of infections, particularly viral infections, including HIV and other infections which may have a latent phase.

- 5      The host cell population which is obtained, or removed, from the host organism may comprise one or more cells, or may comprise a tissue sample which is removed from the body.
- 10     The host cell population which is used according to the invention for a subsequent transplantation procedure to the host organism, may be used at any convenient or desired time after removal from the host organism. In order words a tissue or cell sample removed from an individual may be used at a future date when required for use in therapy. Advantageously, however, the invention permits the subsequent transplantation to be at a prolonged time interval after the cell removal, e.g. from 3 months to many years (e.g. up to 80 years or more). Thus, the invention allows healthy, non-diseased cells to be removed from an individual when in good health, or good immunological status and used, many years later, for therapy of that individual, when a problem develops. Preferred or representative time intervals for subsequent transplantation thus include 6 months to 70 years, 1 to 50 years, and 1 to 30 years or 5 to 30 years. Conventional cryopreservation conditions and procedures allow for such periods (Scand. J. Haematol. 10 (1977) 470; Int. J. Soc. Exp. Haematol. 7 (1979) 113).
- 15
- 20
- 25
- 30

The host cell population may be obtained or removed from the host cell organism in any convenient way. This may depend on the cells and the location in the body from which they are obtained.

When host organism mature T-lymphocyte cells are

- 18 -

sampled, sampling of the peripheral blood and not the bone marrow is required since bone marrow contains few if any mature T-cells. In this instance, i.e. when mature cells are required for transplantation, it is  
5 preferred that peripheral blood is sampled so as to provide a therapeutically beneficial proportion of the mature immune system. The basis for the mature T-cell number required for therapeutic benefit is not fully understood, but may relate to the number of unique  
10 clones of mature T-cells that are represented, and therefore may need to be sampled in the body. Erring on the side of caution it is thought that there are perhaps one hundred million unique clones or more of mature T-cells, comprising memory cells with multiple copies  
15 thereof (Austin JA and Wood KJ (1994) Principles of Cellular Immunology, Oxford University Press, pp 3-61). .

Since the total mature T-cell number per litre of blood ranges between  $1-2.5 \times 10^9$  for humans, a 100 ml sample of  
20 blood typically contains  $1-2.5 \times 10^8$  mature T-cells and this is generally sufficient to provide an adequate representation of the entire mature human T-cell population for the beneficial effect. Moreover, due to the inability to extract all the mature T-cells from  
25 blood with current methods and the loss of viable cells during processing and storage, preferably at least 100 mls, 115 mls, 200 mls or 300 mls and even more preferably in excess of 400 or 500 mls of blood sample should be used in order to obtain the appropriate number  
30 of mature T-cells to support a beneficial therapeutic effect for return to the individual if and when they become ill.

Also, once the individual succumbs to disease i.e.  
35 becomes ill they may not necessarily gain the optimum beneficial effect from one reinfusion of their mature T-cells so that multiple reinfusions may be required

- 19 -

perhaps 2 or even 3 times or more to gain the best possible beneficial effect. If necessary or desired, many more infusions can be given to an individual over time e.g. 4, 5 or 10, 15 or 20 or more infusions may be given. The number of infusions desired may depend on whether the patient to be reinfused is "healthy" (e.g. in remission) i.e. although the patient has been diagnosed as having the disease, the disease may not have progressed so far as to make the patient seriously ill at presentation, or interim treatment regimes may have postponed or alleviated symptoms of the disease to the point that the patient appears to have recovered and is in a temporarily "healthy" state. To ensure the best chance of a beneficial effect, whether the patient is "healthy" or not, it is generally preferable to have sampled at least 450-500 mls of blood from the individual before onset or manifestation of the disease, which is the equivalent of a unit of blood as provided by a blood donor for the UK blood transfusion service, for example. If possible a number of samples i.e. several 450-500 ml samples may be taken over a period of time, e.g. over 2-3 weeks, preferably 2-3 months or over 6 months or a year, 2 or 3 years or more. One or more of these can then be divided or combined into a number of 100ml samples for sequential transplantation treatments, if needed. (Of course during processing, the blood may be fractionated into relevant cellular components for storage.)

The removal of a unit of blood is commonplace with over three million units of blood being taken, for allografting, from individuals annually in the UK alone. The blood removed is soon replaced and, therefore, multiple samplings of a unit of blood from an individual can be provided over a year, say 2-12 unit samplings if necessary, without detriment to the individual being sampled.

- 20 -

As an alternative to removing whole blood from the individual without returning any portion of it immediately to the donor, the mature T-cells may be removed by a process of leukapheresis which is mentioned further below. During leukapheresis, blood is removed from an individual and passed through a cell separator which separates nucleated white blood cells from red blood cells and plasma outside the body. The red blood cells and plasma are returned to the individual, as part of the separation process. The process is continuous with blood being removed and returned almost simultaneously after various extractions have been performed. The process of leukapheresis makes it possible to remove and return the entire blood volume of the individual several times over and separate out and keep large numbers of white cells without detriment to the individual. The current separation systems, such as the Cobe system (Cobe BCT, Lakewood, CO, USA), are capable of extracting between 40% and 50% of the total white cells in the whole blood that passes through the separator, and the flow rate can be 40-60 mls or more per minute.

It is therefore possible to sample far greater numbers of mature T-cells from individuals at any one sitting with this procedure compared to numbers obtained after the removal of a unit of whole blood. Indeed, it is possible to remove 50% or more of the entire white cell population in the circulating blood. Interestingly, removal of such vast numbers of white cells of which lymphocytes are a subpopulation (i.e. about 25% of the white cells are lymphocytes) is not detrimental to the individual, as the circulating lymphocytes, for example, constitute only about 1-2% of the entire lymphocyte population, the majority of which are stored elsewhere in e.g. the bone marrow (in particular immature lymphocytes), spleen, thymus and other organs such as

- 21 -

the lymph nodes. Not surprising, perhaps, is the fact that the white cells removed from the circulating blood by e.g. leukapheresis are replaced within a very short period - perhaps at most 2 hours after the pheresis process has ended.

Experiments are carried out (see the Examples) which demonstrate that the cell number, particularly the total number of T cells in a sample for preservation and use according to the invention may be important.

Advantageously, a minimum T cell count in a sample may be used in accordance with the invention, and this is readily achieved e.g. using samples of peripheral blood.

Hence a sample for use according to the invention i.e. for preservation and autologous transplantation may be obtained either from a single sample taken from a subject, or it may comprise a mixture of cells taken from more than one sample, e.g. it may contain cells such as T cells taken from 2, 3, 4 or 5 or more samples derived from an individual over a period of time.

It is particularly surprising that as few as  $0.1 \times 10^9$ , e.g.  $1-10 \times 10^8$  mature lymphocytes i.e. which can be derived from a single sample of approximately 100 ml of normal human blood, are sufficient to boost the immune system of a subject and hence have a beneficial effect according to the autologous transplantation method of the invention. Thus, even without the benefit of leukapheresis techniques, sufficient blood samples for autologous transplantation can readily be obtained and stored according to the invention for subsequent use by the original donor.

Thus, in a most advantageous aspect of the invention, the number of mature T-cells in a sample for the uses, methods and compositions according to the invention is

- 22 -

at least  $0.1 \times 10^8$ , more preferably at least  $1 \times 10^8$ ,  
e.g. at least  $1-10 \times 10^8$ . The preferred ranges are  $0.1 \times 10^8$  to  $10^{10}$  mature T lymphocytes, such as  $1 \times 10^8$  to  $10^{10}$  or  $1 \times 10^9$  to  $10^{10}$  mature T lymphocytes. T cell numbers  
5 may be increased by *in vitro* expansion using standard methods (see below and the Examples).

As mentioned above, the cells may be derived from a single sample taken from a subject, or it may be derived  
10 from a mixture of cells from a number of samples taken from an individual at different times.

Standard techniques are known in the art which permit selection of particular subpopulations of lymphocytes  
15 from a sample comprising a mixed population of lymphocytes. Examples of such subpopulations are CD3<sup>+</sup>, CD8<sup>+</sup>, CD4<sup>+</sup> and CD16/56<sup>+</sup> (natural killer) T cells and CD19<sup>+</sup> B cells. For example any one or any mixture or combination of such subpopulations of T cells can be  
20 used in the methods, uses and compositions of the invention, and they are readily obtained by means of well known methods such as FACS (Fluorescence activated cell sorting) and haemocytometry systems. See also the Examples for further details.

25 The mature T-cell sample acquired for autologous transplantation is at least  $0.1 \times 10^8$ , generally in the range of  $10^8$  -  $10^{10}$  CD3<sup>+</sup> mature T-cells, preferably  $2 \times 10^8$  -  $10^{10}$ , more preferably  $3 \times 10^8$  -  $10^{10}$  CD3<sup>+</sup> and even more  
30 preferably  $4-5 \times 10^8$  -  $10^{10}$  CD3<sup>+</sup> mature T-cells.

Conveniently, each sample prepared for grafting should contain  $3 \times 10^8$  CD3<sup>+</sup> mature T-cells, more preferably  $5 \times 10^8$  and even more preferably  $1 \times 10^9$  CD3<sup>+</sup> mature T-cells. If sufficient resources of blood are available from an  
35 individual, even more preferably still  $4-5 \times 10^9$  CD3<sup>+</sup> mature T-cells or  $10^{10}$  CD3<sup>+</sup> mature T-cells may be used.

- 23 -

The mature T-cell subpopulation sample acquired for autologous transplantation which is CD3<sup>+</sup> and CD8<sup>+</sup> is at least 0.1x10<sup>8</sup>, generally in the range of 0.25x10<sup>8</sup> - 0.25x10<sup>10</sup>, and more preferably 0.5x10<sup>8</sup> - 0.25x10<sup>10</sup>, and even more preferably 0.75x10<sup>8</sup> - 0.25x10<sup>10</sup>, and even more preferably still 0.75x10<sup>8</sup> - 0.25x10<sup>10</sup> or 1-1.25x10<sup>8</sup> - 0.25x10<sup>10</sup>. Specific CD3<sup>+</sup> and CD8<sup>+</sup> cell numbers in each sample prepared for grafting is conveniently of the order of 0.2x10<sup>8</sup>, preferably 0.6x10<sup>8</sup>, or more preferably 1.2x10<sup>8</sup>, or still more preferably 2x10<sup>8</sup>, or more preferably 3x10<sup>8</sup>, or more preferably 5x10<sup>8</sup>. If sufficient resources from an individual are available, 1x10<sup>9</sup>, preferably 2x10<sup>9</sup>, 4x10<sup>9</sup>, or more preferably 1x10<sup>10</sup> CD3<sup>+</sup> and CD8<sup>+</sup> cells may be used.

15

The mature T-cell subpopulation sample acquired for autologous transplantation which is CD3<sup>+</sup> and CD4<sup>+</sup> is at least 0.1x10<sup>8</sup>, generally in the range of 0.1x10<sup>8</sup> - 0.5x10<sup>10</sup>, and more preferably 0.43x10<sup>8</sup> - 0.5x10<sup>10</sup>, and even more preferably 0.85x10<sup>8</sup> - 0.5x10<sup>10</sup>, and even more preferably still 1x10<sup>8</sup> - 0.5x10<sup>10</sup> or 1.8-3.6x10<sup>8</sup> - 0.5x10<sup>10</sup>. Specific CD3<sup>+</sup> and CD4<sup>+</sup> cell numbers in each sample prepared for grafting is conveniently of the order of 0.4x10<sup>8</sup>, preferably 0.8x10<sup>8</sup>, or more preferably 1.4x10<sup>8</sup>, 1.5x10<sup>8</sup>, 2x10<sup>8</sup>, 3x10<sup>8</sup>, 4x10<sup>8</sup>, or more preferably 5x10<sup>8</sup>. If sufficient resources from an individual are available, 1x10<sup>9</sup>, or more preferably 2x10<sup>9</sup>, or more preferably 1x10<sup>10</sup> CD3<sup>+</sup> and CD4<sup>+</sup> cells may be used.

30

The mature T-cell natural killer subpopulation sample acquired for autologous transplantation which is CD16/56<sup>+</sup> is at least 0.1x10<sup>8</sup>, generally in the range of 0.1x10<sup>8</sup> - 0.5x10<sup>10</sup>, preferably 0.2x10<sup>8</sup> - 0.5x10<sup>10</sup>, more preferably 0.3x10<sup>8</sup> - 0.5x10<sup>10</sup>, and even more preferably still 0.5x10<sup>8</sup> - 0.5x10<sup>10</sup> or 0.5-2x10<sup>8</sup> - 0.5x10<sup>10</sup>. Specific CD16/56<sup>+</sup> cell numbers in each sample prepared for grafting is conveniently of the order of 0.1x10<sup>8</sup>, 0.2x10<sup>8</sup>, 0.3x10<sup>8</sup>,

- 24 -

0.5x10<sup>8</sup>, 1x10<sup>8</sup>, 2x10<sup>8</sup>, 3x10<sup>8</sup>, 5x10<sup>8</sup>, or more preferably, if sufficient resources are available, 1x10<sup>9</sup>, 2x10<sup>9</sup> or 1x10<sup>10</sup> CD16/56<sup>+</sup> cells may be used. Some or all of the CD16/56<sup>+</sup> subpopulation may be, but is not necessarily, 5 also CD3<sup>+</sup>.

In addition, the mature lymphocyte cell sample may preferably include B cells, such as CD19<sup>+</sup> B lymphocytes. The mature B-cell sample included in the T-cell sample 10 is at least 10<sup>7</sup>, 10<sup>8</sup> or 10<sup>9</sup>, generally in the range of 10<sup>7</sup> - 10<sup>10</sup> mature B-cells and preferably 2x10<sup>7</sup> - 10<sup>10</sup> mature B-cells, more preferably 3x10<sup>7</sup> - 10<sup>10</sup> mature B-cells, and even more preferably 4-5x10<sup>7</sup> - 10<sup>10</sup> mature B-cells. Specific numbers of B-cells in each sample prepared for 15 grafting is conveniently of the order of 3x10<sup>7</sup>, preferably 5x10<sup>8</sup>, more preferably 1x10<sup>9</sup> mature B-cells, and even more preferably still 4-5x10<sup>9</sup> or 10<sup>10</sup> mature B-cells.

Recent advances have been made in the way cells may be obtained for subsequent grafting. The advent of molecular biology has helped us to understand more clearly the basic biology of cell growth and function in health and disease. For example, investigations into 20 the agents which regulate haematopoiesis have led to the isolation of a series of factors that influence the proliferation and differentiation of lymphocytes - these include the cytokines such as the interleukin series IL-1-IL-18 and the leukotrienes; and growth factors such as the TNF's, the TGF's, FGF's, EGF's, GM-CSF, G-CSF and others. A number of these factors are now available commercially for clinical use, and some have been shown 25 to increase substantially the number of lymphocytic cells and, in particular, immature T-lymphocytes in the peripheral blood. Their administration to the host organism means that, after a few days to allow an 30 effect, it is possible to filter large quantities of the 35

- 25 -

cells of interest, eg. immature T-lymphocytes, directly from host's blood without the need to sample the marrow (Stem Cells 15(1997) 9). The technology for extracting lymphocytes from blood, by removing blood from the 5 subject, passing it through a cell separator and then returning it to the patient, all virtually simultaneously, has been available for many years (Practical Immunology, 3rd Edition, Blackwell Scientific Publications, 1989). This is the process of 10 leukapheresis as mentioned above.

Biopsy procedures may also be used to facilitate removal of other cell types, or cells from other locations. For example, Example 5 describes how brain cells may be 15 obtained. Gut samples may be obtained, e.g. from stomach, intestines or rectum, by endoscopic biopsy. Fine needle aspiration may be used for thyroid or other tissues.

20 Selective cell isolation procedures for desired cell types may also be possible, see e.g. JP-A-10033165 (Abstract) for selective isolation of haemopoietic undifferentiated cells.

25 The removed host cell population may be stored, cultured, handled, manipulated or treated in any known or desired manner for subsequent transplantation (i.e. to prepare the cell composition for transplantation). Cell handling, culture and storage procedures are well 30 known in the art and widely described in the literature, and any of the standard procedures may be used. Cells may be stored in any convenient or desired medium, e.g. as known in the art. (See e.g. Freshney's (supra) for cell culture requirements and WO 98/33891 for lymphocyte 35 preparation).

In a preferred aspect of the invention, the host cell

- 26 -

population further comprises or has been treated with a stimulatory molecule. The host cell population may be treated for example in vitro, by culturing the sample in the presence of stimulatory molecules such as cancer or 5 viral antigens, T cell epitopes, peptides, blood factors, growth factors or cytokines or combinations thereof.

These molecules may be synthetic or recombinant or may 10 be purified or isolated from the human or animal body. Alternatively, the host cell population may be treated in vivo, e.g. growth factors or cytokines can be administered to the host organism either prior to sampling of the host cells, or they can be administered 15 in a separate composition, sequentially or simultaneously with the host cell population, or alternatively they can be added to the host cell population immediately prior to infusion.

Such procedures are well known in the art, as are the 20 different types of stimulatory molecule e.g. various growth factors and cytokines which may be employed. Particular mention may be made for example of IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IL-1 $\alpha$ , IL-1 $\beta$ , IL-2, IL-3, IL-4, IL-5, IL- 25 6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, GM-CSF, M-CSF, G-CSF and LT, although any other stimulatory molecule as mentioned above may be used to expand the host cell population prior to, during or after infusion into the host organism.

Conveniently, the host cell population may be put into a 30 state of dormancy. The term "dormancy" as used herein includes any state of suspended animation or stasis, and procedures for achieving this are well known in the art, 35 as described above. Any of the known procedures may be used (see e.g. Freshneys, supra). Thus, the cells may be held or maintained in a quiescent, inactive or non-

- 27 -

proliferating state.

According to a preferred procedure, the cells are frozen preferably to a temperature below -160°C.

5

A particularly preferred means of achieving dormancy is to freeze the cells to the boiling point of helium (He) ie. to about -269°C or below.

- 10 Thus, in a further aspect, the present invention provides a method of making and/or maintaining cells dormant, said method comprising freezing said cells to a temperature at or below -269°C.
- 15 Dormant cell populations obtained by such a method also form part of the invention.

As described in Freshneys (supra), the cells may be suspended in a suitable medium (e.g. containing 5-10% DMSO) and cooled at a controlled rate e.g. 1°C per minute to -70°C, then into liquid/gas N<sub>2</sub>. Such conventional procedures may be adapted to cool the cells into He/N<sub>2</sub> mixtures or He.

25 Results have been obtained which show that by using the (ie. the lower temperature) improvements in the long-term viability of the cells may be obtained. When multiplied over 10-20 years for example, this enhancement in viability may be important in the 30 successful storage of the cells (see Example 6 below).

Alternative methods of achieving and/or maintaining cell dormancy include cooling to 4°C.

35 The cells may be cultured if desired, for example as part of a treatment or modification process (see later) or they may be expanded ie. they may be cultured to

- 28 -

increase cell numbers. For example, the cells may be passaged, according to methods well known in the art. The culturing may be before or after the period of dormancy, or both.

5

Prior to transplantation, the cells may also or alternatively be modified or manipulated in some way, e.g. genetically or functionally and/or by inducing or modulating their differentiation. Again, as described 10 above, this is known in the art and any of the known or standard procedures may be used. (see e.g. WO98/06823, WO98/32840, WO98/18486). Such modification or manipulation may be carried out before or after dormancy, or both. The modification/manipulations are 15 not restricted temporally, in that the sequence and/or number of manipulations is flexible.

Thus, genetic interventions may include regulating or modifying the expression of one or more genes, e.g. 20 increasing or decreasing gene expression, inactivating or knocking out one or more genes, gene replacement, expression of one or more heterologous genes etc. The cells may also be used as a source of nuclei for nuclear transfer into stem cells.

25

The cells may be exposed to or contacted with factors, e.g. cytokines, growth factors etc. which may modify their growth and/or activity etc, or their state of differentiation etc. The cells may also be treated to 30 separate or selectively isolate or enrich desired cell types or to purge unwanted cells.

Thus, for example a T-cell modulatory method is discussed above, whereby T-cells are co-stimulated prior 35 to transplantation.

Alternatively, haematopoietic cells may be co-presented

- 29 -

with HLA class I restricted tumour antigen and B7 and/or IL12, so as to produce both activated and memory T-cells. The sample may then returned to the host organism before the onset of disease, as a prophylactic therapy. Alternatively, the co-presenting antigen-presenting cells (APCs) may be returned to the host along with the activated and/or memory T cells. Alternatively, the cells may be exposed to the host's tumour *in vitro* with appropriate danger signals and co-presentation of co-stimulatory molecules, before being returned to the host. As with our WO96/15238 directed to T-lymphocyte therapy, the host's CTLs may be genetically modified to recognize the tumour prior to replacement. The alternatives in this paragraph provide for functional interactions between haematopoietic cells either prior to, or after a period of dormancy or combination.

Following dormancy, the cells are revitalised prior to use in transplantation. Again, this may be achieved in any convenient manner known in the art, and any method of revitalising or reviving the cells may be used.

Conveniently, this may, for example, be achieved by thawing and/or diluting the cells, e.g. as described in the Examples. Techniques for revitalisation are well known in the art (see e.g. Freshney's *supra*). Cells may be thawed by gentle agitation of the container holding the cells in water at 37°C, followed by dilution of DMSO to 1% or below, e.g. with medium, or patient serum etc. Cells may be implanted immediately or after recovery in culture. Revitalisation is designed to re-establish the usefulness of the cells e.g. in prophylaxis or curative therapy.

The invention relates to the recognition that a tissue sample from a non-diseased individual may be put into a

- 30 -

state of dormancy. The tissue may then be revitalized and returned to the same individual when required at a later date. Grafting the revitalized tissue 1, 2, 3, 4, 5, 6 or more months or 1, 2, 3, 4, 5, 6 or more years 5 after its removal from the patient is intended to alleviate or protect against disease, to slow the progression of disease, or to augment and/or support the functioning of the remaining normal, or damaged, tissue in the patient. The invention is clearly distinct from 10 the freezing of bone marrow cells from patients with eg. leukaemia, and from the freezing of gametes, eg. sperm, prior to treatment of patients with eg. childhood leukaemia, because the patients already have disease. It is also distinguished from patients who provide blood 15 for chilled storage for possible later use, eg. at a subsequent operation, for the same reason. In addition, the duration of storage for the possible return of such a blood sample is commonly only up to one month. Similarly, individuals with no diagnosed abnormality may 20 choose to provide blood for chilled storage for prospective use by themselves prior to travelling abroad. Such use might include for the treatment of hypovolaemia after acute blood loss, such might occur after a road traffic accident or other trauma, but this 25 again is for a short period of storage of about one month only, and not intended for use in future disease e.g. chronic disease.

A number of particularly advantageous applications of 30 the invention can be identified. Firstly, for individuals who are predisposed to blood disorders such as leukaemia or lymphoma but have not succumbed to, or are asymptomatic for, the disease prior to sampling, the invention provides a prospective therapeutic method. It 35 would be beneficial for such presently healthy individuals to provide a tissue sample or multiple tissue samples (eg. bone marrow or blood). The sample/s

- 31 -

could be kept in a state of dormancy until their use at a future date to replace/augment aberrant or lost tissues/cells and alleviate the disease they were likely to contract after the sample was taken. The invention  
5 may also have applicability for individuals whose environments pre-dispose them to e.g. leukaemia, for example power station workers. The invention is against all conventional teachings, then, which recommend retrospective allografts or autografts to provide a  
10 curative intervention in diseases such as leukaemia and lymphoma or solid tumours. Other types of pre-disposition are also included within the scope of this aspect of the invention, as indeed are other factors e.g. a family history which might suggest a risk of a  
15 suspected condition.

A further advantageous utility of the invention is in the treatment of HIV infection or disease. Thus, CD4<sup>+</sup> cells can be collected from an individual when healthy  
20 or non-infected, and stored for subsequent transplantation into said individual when HIV infection manifests itself or when AIDS develops, or CD4<sup>+</sup> cell count falls etc. Such a procedure may be attractive to an individual with a life-style likely to place them at  
25 risk from contracting HIV infection.

In addition, it is well recognized that the ageing process makes individuals more susceptible to disease. The basis for the susceptibility appears to be in the  
30 loss of immune function resulting from a significant decrease in T and B cell numbers/activity during ageing (Mech Ageing & Dev 91(1996)219; Science 273(1996)70; Mech Ageing & Dev 96(1997)1).

35 Furthermore, the invention can be seen as being particularly advantageous in the light of recent discoveries related to the down-regulation of cytotoxic

- 32 -

T-lymphocyte activity in response to HLA class I antigen-restricted tumour-epitope presentation.

Disease susceptibility is particularly pertinent when  
5 elderly patients are subjected to eg. surgery in a hospital environment, where they are prone to opportunistic infections with serious or even fatal consequences. Marrow and/or blood samples taken much earlier in life from the patient, such as during  
10 adolescence or early adulthood when their immune system is mature but uncompromised, and maintained subsequently in a state of dormancy, could be revitalized and reinfused to the patient to boost their immune system. Such an approach would provide for a method of  
15 augmenting the patient's immune system after surgery in order to lessen the likelihood of post-operative complications caused by opportunistic infections. The invention, therefore, could be used as a prophylactic therapy, eg. for elderly patients when they are more  
20 susceptible to disease.

Another area in which the invention can be seen to have particular advantages is where individuals may be predisposed to endocrine disorders in later life such as  
25 diabetes, hypothyroidism or hypoparathyroidism, or to the loss or disease of skeletal material leading to age-related osteopaenia, osteoporosis, osteoarthritis, rheumatoid arthritis, and periodontal disease. Tissue/cell samples could be taken from these individuals,  
30 stored in a state of dormancy, and then reinfused back, optionally after *in vitro* expansion, into the individual when their endocrine/skeletal status indicated a requirement.  
35 The recent discovery that neural stem cells exist in even the adult brain means that sampling from eg. the ventricular surface of the brain will permit expansion

- 33 -

in vitro of such stem cells to provide large neural cell populations. These may then be used as a source of material for grafting back to the same individual who may in the meantime have succumbed to, or become symptomatic for a neural disease or disorder eg. Parkinson's disease, Huntington's chorea, multiple sclerosis, stroke injury, Alzheimer's disease, amyotrophic lateral sclerosis, Pick's disease, Creutzfeld-Jacob disease or other neurodegenerative disorders. Furthermore, the invention has particular advantages in the treatment of neurodegenerative illness with a genetic component. This is because the donor cells can be modified genetically, either before or after dormancy to, for example, override, negate, alleviate or reverse the effects, future or current, of the abnormal inherited component of the disease. In Huntington's chorea, for example, the IT15 gene coding for Huntington contains an abnormally large number of CAG repeats (Cell 72 (1993) 971). This dominant gene may be inactivated or knocked out in vitro, and replaced by the normal version (J. Neuro Sci: 18 (1998) 6207; Bioessays 20 (1998) 200). The present invention has clear advantages, therefore, in the treatment of neurodegenerative disease, by providing graftable (PNAS 89 (1992) 4187), and in this case autograftable material, both with and without prior modification of the cell's functionality, differentiation or genotype. Analogous principles would apply to the treatment of other diseases or disorders.

The invention would also have advantages where cell/tissue samples need to be transported to specialist laboratories to undergo manipulations (eg. genetic modifications e.g. nuclear transplantation into stem cells) prior to their return to the patient. Often, it may not be possible to treat/modify the cells, either genetically or functionally, or phenotypically at the

- 34 -

place where the patient is sampled. Even if it is possible, the process may not be immediately initiatable. Placing the sample in a state of dormancy may be considerably advantageous to the procedure, as  
5 the cell manipulations that need to be made can be performed at a time suitable to the management of the process eg. either before making the cells dormant or after they are resuscitated, but before they are returned to the patient.

10 The invention would be seen also as advantageous when a multiplicity of samples from a single donor are needed. The invention could be used to build a stock by multiple sample additions (i.e. 2 or more) to the first sample,  
15 all of them being placed in a state of dormancy prior to revitalizing part of, or the complete collection for use, for example, in therapy. The donor tissue for autografting may be from animals including transgenic animals. Such animals would include, but not be limited  
20 to, rats, mice, pigs, dogs, cats, sheep horses and cattle.

The invention may also include the incorporation of a negative selection marker into all cells/tissues  
25 destined to be returned to the patient as described, for example, in WO96/14401 (Transgenic organisms and their uses), and WO96/14400 (Genetically modified neural cells) the contents of which are incorporated herein by reference.

30 The invention will now be described in more detail in the following non-limiting Examples, with reference to the drawings in which:

35 Figure 1 is a histogram showing the effect of reinfusion of cryopreserved autologous white cells on survival of X-irradiated rats (numbers of surviving rats vs Time

- 35 -

(weeks) after irradiation). Rats were maintained under SPF (specific pathogen-free) conditions. Five ml of whole blood was removed by cardiac puncture from all rats two weeks prior to irradiation. White cells were prepared as described earlier from five of the blood samples and then cryopreserved using standard procedures (see Example 1). At time zero, all rats were given 8 Gy of X-irradiation. Two weeks following the irradiation five rats (solid bars) were infused with autologous grafts of thawed white cells and control animals (striped bars) received autologous grafts of thawed white cells and control animals (striped bars) received autologous plasma vehicle alone. Two days later, all rats were removed from SPF conditions and returned to the main animal housing facility. Death of animals through opportunistic infection was monitored. The experiment demonstrates that reinfusion of white cells into irradiated rats protects such immune-depleted animals from death by infection.

Figure 2 is a histogram showing maintenance in grafted rats of autologous, engineered T-lymphocytes up to six months after grafting, the full period of study (numbers of rats vs time (months)). Five ml of peripheral blood was removed from each of ten rats by cardiac puncture. The white cells were enriched from the samples as described in Example 1 and then genetically engineered to contain the hygromycin resistance gene (WO96/15238). The cells were cryopreserved as described earlier. Six months after cryopreservation, the cells were thawed and autologous reinfusion performed. The presence of DNA encoding the hygromycin resistance gene was analyzed by PCR at three-monthly intervals. The experiment shows the continuing presence of hygromycin-resistance gene-containing cells.

Figure 3 is a histogram showing the results of an

- 36 -

identical study to that described in Figure 2, except  
that the genetic engineering step was performed after,  
rather than before the cryopreservation stage. The  
presence of DNA encoding the hygromycin resistance gene  
5 was analyzed by PCR at three-monthly intervals. Similar  
results to those found with a pre-preservation  
engineering step were obtained, indicating the prolonged  
survival of the cells after return to the host.

10 Example 1

Survival of infection through prospective autologous  
grafting of frozen stored donor cells

15 (i) Samples taken

Both male and female Wistar rats were used in this  
study. A number of standard procedures were employed to  
extract either marrow samples or peripheral blood  
samples (see below). Reference to these procedures can  
20 be found in human or animal surgical texts such as that  
by Waynfirth and Flecknell (*Experimental and Surgical  
Technique in the Rat*, 2nd Edition, Academic Press,  
1992).

25 (ii) Methods of sampling

In brief, animals were anaesthetised with chloroform and  
anaesthesia was maintained with halothane. Bone marrow  
cells and/or blood cells were sampled using standard  
procedures. All sampling was performed under  
30 anaesthesia. Blood was sampled by cardiac puncture, or  
by exposure of the jugular vein followed by blood  
extraction therefrom. Marrow was extracted from the  
femur after a hind leg amputation; and from the tibia  
and fibula of the amputated hind leg. (*Practical  
Immunology*, 3rd Edition, Blackwell Scientific  
Publications, 1989). For marrow sampling the rat femur  
35 and/or tibia was exposed and bone marrow cells removed

- 37 -

using disposable bone aspirating needle(s) or an Islam bone marrow harvesting needle, or equivalent thereof, for rats. Several areas of the bone were sampled so as to provide an adequate harvest of marrow cells for  
5 future needs. Alternatively, a rib biopsy was taken which was particularly advantageous for the sampling of bone cells of the CFU-F (colony forming units-fibroblast) type. For humans, the iliac crest is usually sampled.

10

(iii) Marrow cell preparation

Once obtained, the marrow cells were suspended in culture medium and separated from fatty materials essentially as described previously for human cell  
15 sampling (Bone 22(1998)7). The resulting cell suspension was transferred to a universal container and allowed to stand undisturbed for 10 minutes (min), after which time fat deposits that had floated to the top were removed. The marrow-derived cells were transferred to a  
20 centrifuge tube and spun at 100 x gravity (g) for 5 min to harvest the cells. The medium and fat deposits were again removed and the cell pellet resuspended in 5 ml of fresh culture medium. The resuspended cells were loaded onto a 70% Percoll gradient which was centrifuged at 460 g for 15 min. Following centrifugation, the top 25% of the gradient volume, which contained the required marrow cells, was removed. To this suspension an equal volume of fresh medium was added and the suspension centrifuged at 100 g for 10 min. The resulting cell pellet was  
25 resuspended in fresh medium and a single cell solution obtained by passing the cells through a 19-gauge needle several times. The number of viable cells was then determined by trypan blue (1% w/v) exclusion.  
30  
35 Alternatively, no separation of the fat cells from the sampled marrow cells was carried out, and the entire sample was prepared for dormancy. Both

- 38 -

- haematopoietically-derived and mesenchymally-derived tissues could be obtained by marrow sampling such that, in addition to cells of the immune system, cells capable of giving rise to osteoblasts, chondroblasts, myoblasts, fibroblasts and/or adipocytes could be also obtained. .  
5 The mesenchymal cells can be separated, for example, by taking advantage of their adherent properties. Placing the sampled cells on standard tissue culture plasticware, for varying lengths of time, leads to adherence of the mesenchymal cell population to the plastic, leaving the haematopoietic cells in suspension.  
10 The different cell types can be then physically separated by pouring off the supernatant.  
15 All of the above procedures are well known to the man skilled in the art.

(iv) Peripheral blood sampling

- Adequate samples of mononuclear cells (white cells) were obtained, alternatively, by peripheral blood sampling.  
20 It is well recognised that haematopoietic stem cells, progenitors of T-lymphocytes and mature T-lymphocytes reside in peripheral blood which makes peripheral blood mononuclear cells suitable for transplantation.  
25 Peripheral blood was also sampled from rats given an intraperitoneal injection/s of either granulocyte colony stimulating factor (G-CSF) or granulocyte macrophage colony stimulating factor (GM-CSF) or haemopoietin for periods up to 96 hours prior to sampling. The peripheral blood mononuclear cells were sampled 1 to 4 days after G-CSF/GM-CSF administration. G-CSF and GM-CSF have been shown to increase the peripheral blood mononuclear cell population which comprises  
30 haematopoietic T-lymphocytes and their progenitors and stem cells, as well as other blood cells. This approach, therefore, helps to increase, *in vivo*, the  
35

- 39 -

abundance of cells required for subsequent transplantation prior to their removal from the body. The use of agents such as G-CSF, GM-CSF, haemopoietin or combinations thereof 3-4 days prior to sampling of blood by aphaeresis is a method currently used to obtain peripheral blood stem cells for human therapy and may be used in the invention (Stem Cells 15(1997)9).

(v) Isolation and storage of sampled cells  
10 Peripheral blood from either non-treated or GM-CSF/G-CSF-treated rats was taken, and white cells prepared directly using standard procedures. In short, blood samples were placed in heparinised tubes and high purity lymphocyte preparations obtained by differential  
15 centrifugation on a density gradient. After centrifugation, the white cell - containing buffy coat (white cell band), which was clearly visible, was removed to a fresh cryopreservation container (Practical Immunology, 3rd Edition, Blackwell Scientific Publications, 1989).

Alternatively, the marrow cell samples (either non-separated samples, or samples separated into different cell types - e.g. fat/non-fat, mesenchymal/haematopoietic cells) collected were placed in fresh cryopreservation containers.

To the blood or marrow samples autologous plasma containing 20% v/v DMSO (or variations of DMSO volume from 5-50%) was added to a final volume that brought the DMSO concentration to approximately 8.25 % (or variations of DMSO volume from 8-50%). The samples were then refrigerated and slowly frozen so as to lose approximately one degree Celsius every 1-2 min until they reached approximately minus 50°C. They were then transferred to gas/liquid-phase nitrogen/helium, or gas and/or liquid nitrogen followed by gas and/or liquid

- 40 -

helium for long term storage at approximately minus 196°/269°C until required.

Rats sampled were given several weeks to recover prior  
5 to undergoing further treatment(s).

(vi) Replenishment of the immune system

One group of 10 sampled rats received an ablative dose (8 Gy) of whole body irradiation so as to destroy  
10 radiation-sensitive cell populations. The radiation dose given has been shown to compromise the immune system which is highly radiation-sensitive, such that animals die readily from infection soon after treatment (Practical Immunology, 3rd Edition, Blackwell Scientific  
15 Publications, 1989). Removal of the thymus may have a similar effect.

Marrow cells or white cells were thawed from frozen,  
with gentle agitation of the cryovial in a beaker of  
20 37°C water. Medium was then added to dilute the DMSO eg. 10-fold, and the cells gently pelleted by centrifugation at 400g. The cells were resuspended in a small volume of autologous plasma before being returned to the animal by infusion.

25 Of the 10 irradiated animals, 5 were given autologous grafts two weeks after irradiation, and all rats returned to the animal unit's main housing facility. Within three months the 5 non-autografted rats had died  
30 from infection, but the 5 autografted rats all survived the following six months of the study (see Figure 1).

Example 2

35 Autologous grafting of genetically engineered stored frozen donor lymphocytes

- 41 -

Both male and female Wistar rats were used in the study and marrow cells and/or peripheral blood mononuclear cell samples were obtained as described in Example 1. The mononuclear cells were genetically engineered to  
5 express the a and b chains of the T-cell receptor which, when combined, recognised the Mage 1 tumour antigen. The genetic construction also provided hygromycin resistance to the engineered cells and is described further in WO96/15238 - Targeted T-lymphocytes,  
10 incorporated herein.

Samples of the engineered cells were then cryopreserved for periods up to six months before being revitalised/revived as described in Example 1 and used  
15 as autologous grafts. Rats with autologous grafts were sacrificed at various times after grafting, and their blood ex-sanguinated by heart puncture. Genomic DNA encoding the hygromycin resistance gene, present in the engineered cells only, was detected by the polymerase  
20 chain reaction (PCR) as described previously (PCR A Practical Approach, IRL Press, 1991). In brief, peripheral blood mononuclear cells were isolated by differential centrifugation on a density gradient. The buffy coat was separated and genomic DNA prepared by  
25 phenol/ chloroform extraction followed by ethanol precipitation and resuspension in sterile water (Sambrook et al., Molecular Cloning. A Laboratory Manual, Vols. 1-3, Cold Spring Harbour Laboratory Press, 1989). The genomic DNA was PCR amplified in the  
30 presence of oligonucleotide primers designed to recognise a 272 base pair sequence of the hygromycin resistance gene (see McPherson et al., PCR. A Practical Approach, IRL Press, 1993 for PCR conditions).  
35 Hygromycin primers detecting hygromycin gene sequence of size 1.023 kb were as follows:  
GAATTCAGCGAGAGCCTGAC (left primer 5'-3')  
GATGTTGGCGACCTCGTATT (right primer 5'-3')

- 42 -

A sample of the PCR product was electrophoresed through  
a 4% agarose gel and the 272 base pair fragment of the  
hygromycin resistance gene identified by UV  
transillumination after staining the gel with ethidium  
5 bromide. The ability to identify the hygromycin gene in  
the rat blood samples over time is provided in Figure 2.

Example 3

10 Genetic engineering and autologous grafting of stored  
frozen donor lymphocytes

15 Example 3 was performed as for Example 2, except that  
the cells for autologous grafting were cryopreserved  
prior to genetic engineering. Samples were thawed as  
described in Example 1 prior to autografting.

Results of the maintenance of gene expression in the  
autograft over time is given in Figure 3.

20

Example 4

Syngeneic and autologous grafting of marrow stromal  
cells in young and aged rats

25

An inbred strain of Sprague Dawley rats was used for  
these studies. Suspensions of bone marrow cells ( $2 \times 10^6$   
cells per ml) were prepared from rib (also femur)  
biopsies taken from young rats (8 weeks of age) and aged  
30 rats (60 weeks of age). Cell samples were centrifuged  
at 400 X gravity and the resulting cell pellet(s)  
resuspended in 10% DMSO in autologous plasma followed by  
cryopreservation in liquid nitrogen and/or followed by  
liquid helium.

35

Cell samples were revitalised from 3 months to 2 years  
after cryopreservation and suspended in culture medium

- 43 -

at  $2 \times 10^6$  cells/ml. To each sample suspension a single porous hydroxyapatite disc was added and left for 24 hours to allow cells to adhere to it - producing a cell/HA composite. The composites were then implanted 5 subcutaneously as either autogenous or syngeneic grafts. The grafts were removed after 8 weeks and subjected to histological analysis, and osteocalcin and alkaline phosphatase measurements.

10 The experimental groups were as follows

(1) Marrow cells sampled from young rats aged 8 weeks were incubated with porous hydroxyapatite (HA) for 24 hours to form a marrow cell/HA composite. The 15 composites were then either (a) autogenously grafted or (b) syngeneically grafted to rats of the same age or (c) rats of 60 weeks of age, or (d) rats of 104 weeks of age.

20 (2) Marrow cells sampled from old rats aged 60 weeks were incubated with porous hydroxyapatite for 24 hours to form a marrow cell/HA composite. The composites were then either (a) autogenously grafted or (b) syngeneically grafted to rats of 8 weeks of age or (c) 25 syngeneically grafted to rats of 60 weeks of age, or (d) syngeneically grafted to rats of 104 weeks of age.

(3) Marrow cells sampled from young rats aged 8 weeks were cryopreserved as described. After 96 weeks 30 cryopreservation, the cells were revitalised and incubated with porous hydroxyapatite for 24 hours to form a marrow cell/HA composite. The composites were then either (a) autogenously grafted (the sampled rats being 104 weeks of age) or (b) syngeneically grafted to 35 rats of 104 weeks of age or (c) syngeneically grafted to rats of 8 weeks of age.

- 44 -

(4) Marrow cells sampled from old rats aged 60 weeks were cryopreserved as described. After 44 weeks cryopreservation, the cells were revitalised and incubated with porous hydroxyapatite for 24 hours to 5 form a marrow cell/HA composite. The composites were then either (a) autogenously grafted (the sampled rats being 104 weeks of age) or (b) syngeneically grafted to rats of 104 weeks of age or (c) syngeneically grafted to rats of 8 weeks of age.

10

#### Results

Qualitative histological analysis demonstrated a clear difference between the ability of young and old marrow 15 cells to induce new bone formation in either autogenous or syngeneic grafts. 40% of old marrow cell/HA composites showed no bone formation when grafted to either young or old rats, whereas bone was formed in all composites comprising young marrow cells. The result 20 was identical for composites where the marrow cells had been cryopreserved and revitalised prior to grafting.

Differences in osteocalcin expression and alkaline phosphatase activity between composites formed from 25 young and old marrow cells was highly significant. On average, osteocalcin expression was 8-10 fold higher in composites containing young cells when compared to composites containing old cells. The 8-10 ratio of osteocalcin expressed between composites comprising 30 young compared to composites comprising old cells did not vary significantly due to cryopreservation and revitalisation, or because of syngeneic rather than autologous grafting.

35 Alkaline phosphatase activity was also seen to vary between composites comprising either young or old cells. Composites comprising young cells had 4-6 fold the

- 45 -

alkaline phosphatase activity of old cell composites. Similar to the osteocalcin study, no significant change to this ratio was brought about by cryopreservation of cells prior to forming the composites; or from syngeneic 5 grafting rather than autografting.

Table 1 below discloses the ratios of osteocalcin expression seen between the different groups:

10 Table 1

	Group x/Group y	Ratio
	1a/1b	1.3
15	1a/1c	1.4
	1a/1d	1.5
	2a/2b	0.9
	2a/2c	1.4
	2a/2d	1.6
20	3a/3b	1.0
	3a/3c	1.0
	4a/4b	1.3
	4a/4c	0.9
	1a/2a	9.7
25	3a/4a	9.8
	1a/3a	1.4
	2a/4a	1.4

Table 2 below discloses the ratios of alkaline phosphatase expression seen between the different groups:

30 Table 2

	Group x/Group y	Ratio
	1a/1b	1.1

- 46 -

1a/1c	1.3
1a/1d	1.3
2a/2b	1.3
2a/2c	1.5
5 2a/2d	1.8
3a/3b	1.1
3a/3c	0.9
4a/4b	1.3
4a/4c	0.9
10 1a/2a	5.8
3a/4a	5.9
1a/3a	1.1
2a/4a	1.1

15 Similar differences in bone forming ability, and in bone gla protein and alkaline phosphatase activity, between marrow cells from young and old rats has been reported independently by Inoue et al (1997) using syngeneic rats. However, Inoue et al have not reported the  
20 effects of cryopreservation on the osteogenic ability of young and old cells, and whether this clear difference in young and old cell osteogenic ability holds true for autogenous grafts.

25 Example 5

Autologous grafting of neural cells to adult rats

30 Adult rats at 3 months of age were placed in a stereotaxic frame, and the area of skull overlying the lateral ventricle at the level of bregma was removed. A blunt-ended, sterile glass micropipette (ID = 100 mm) was inserted into the brain 1.4 mm lateral to the midline. The pipette was lowered into the dorsal part  
35 of the lateral ventricle at which point, with controlled suction, a small amount of cerebrospinal fluid (CSF) was withdrawn. Still with controlled suction, the pipette

- 47 -

was further lowered so that it passed through the ventricular, subventricular and other layers of neural tissue situated each side of the lateral ventricle. A suspension of tissue, cells and CSF collected in the 5 large diameter part of the pipette. At the end of the biopsy, the suspension was triturated (sometimes with prior enzymatic digestion with eg. trypsin) and ejected into a small tissue culture flask containing medium. Such medium comprised a mixture of Dulbecco's modified 10 Eagle's medium and Ham's F12 (50/50 v/v) supplemented with L-glutamine (2mM), penicillin:streptomycin (100 IU/ml: 10 mg/ml) and modified stock solution (PNAS USA 76(1979)514; J Neurophysiol 40(1981)1132) containing 10 ng/ml epidermal growth factor (EGF), 5 ng/ml basic 15 fibroblast growth factor (FGF), or the like. Sometimes, transmembrane co-culture with replicative neural cells, or conditioned medium from such cells was also used to support the survival of the newly-dissociated adult cells.

20 The clusters of replicating cells were expanded, and "passaged" by sectioning into 4 - 6 parts followed by replating. This allowed prolonged expansion. Cell clusters, or mechanically dissociated cells derived from 25 them, were frozen either at this stage, or after differentiation (vide infra), in medium containing 10% DMSO and using conventional methods. They were then placed in gas/liquid phase nitrogen followed by prolonged storage in gas/liquid phase helium for periods 30 of up to or including one year.

Thawed frozen replicative cells, or cells from 35 dissociated replicative clusters were replated in roller tubes and allowed to differentiate in the same medium, but without EGF, for the next few days. Some cells were differentiated in the presence of medium conditioned with confluent (but still replicative) striatal cells to

- 48 -

provide both support and differentiation-directing/  
inducing factors. Thereafter, the resulting  
differentiated cell clusters (approximately 1 million  
cells) were injected into the original donor rats  
5 lesioned 10 days earlier unilaterally by intrastriatal  
injection of ibotenic acid. Alternatively, the cells  
were frozen as described above, and then thawed and  
injected into the lesioned striatum. Three months later  
the animals were fixed by perfusion, and the grafts  
10 analyzed by immunohistochemistry.

Surviving transplants were found in all grafted animals.  
The implants were well integrated into the host  
striatum, although they could still be clearly  
15 demarcated as an area through which myelinated fibre  
bundles mostly failed to grow. The proportion of  
surviving grafts was not affected by whether the donor  
cells had been frozen at any stage. Indeed, those  
animals with cells that had been through a freezing  
20 procedure possessed larger grafts than non-frozen cells,  
and the expression of neurofilament in such grafted  
cells also appeared to be more intense and extensive.  
Similarly, some GFAP expression could be seen in the  
graft.

25

Example 6

Effects of storage temperature on cell viability after  
one year

30

Duplicate aliquots of the cells of the type shown were  
frozen by methods described in the text, and at the end  
of 1 hour of cooling at 1°C per minute were placed in  
liquid nitrogen for 1 hour. At that time, one of each  
35 pair of aliquots was thawed by the methods described in  
the text, and analyzed for cell viability using ethidium  
bromide exclusion/acridine orange incorporation (Brain

- 49 -

Res 331 (1985) 251). The other aliquot was placed in liquid helium for approximately one year, and then thawed and cell viability assessed by the same process. The results are shown in Table 3 below. Figures are the means and SEM of 6 sample pairs, and are expressed as a proportion of the cells surviving after 1 hour in liquid nitrogen. It will be seen that the lower temperature can lead to a small but significant enhancement of the viability of the cells in the long term.

10

Table 3

Cell type	Storage condition	
	Liquid nitrogen	Liquid helium
Human neural cell line	90.17±1.64	97.55±0.43
Human white cells	87.61±2.38	96.90±0.92
Human marrow stromal cells	89.85±1.39	97.13±0.77

20

Example 7

Effects of storage temperature on cell viability after two years

25 The "one year" study of Example 6 was repeated, storing an aliquot of cells in liquid helium for 2 years. The cells were then thawed and cell viability was assessed as described in Example 6. The results are shown in Table 4. Figures are the means and SEM of 6 sample pairs, and are expressed as a proportion of the cells surviving after 1 hour in liquid nitrogen. It will be seen that, after two years storage similarly good viability results may be obtained.

30  
35

- 50 -

Table 4

Cell type	Liquid nitrogen	Liquid helium
Human neural cell line	$89.28 \pm 2.51$	$97.08 \pm 1.32$
Human white cells	$88.19 \pm 0.96$	$96.98 \pm 1.41$
Human marrow stromal cells	$86.20 \pm 1.67$	$97.56 \pm 0.93$

5 A series of human clinical trials are disclosed in  
Examples 8 to 14 below to demonstrate the clinical  
10 benefit of autologous grafting of T-lymphocytes, and  
specific sub-populations of T-lymphocytes:

Example 8

15 One unit (450-500 mls) of peripheral blood is withdrawn  
from each of 50 healthy males aged 24-48 years into a  
Baxter R7481 blood pack (bag plus connected  
fractionation bags). The blood is then separated into  
20 three layers with the plasma layer uppermost, the red  
cell layer lowest and the white cell layer in between,  
by centrifugation (at e.g. 1200g for 15 minutes at 18°C)  
in a Beckman J6 centrifuge.

25 After centrifugation, each blood pack is carefully  
removed from the centrifuge bucket of the rotor so as to  
minimise disturbance of the layers, and placed  
individually on an Opti II optipress machine. A  
programme is set so as to press the blood pack and  
squeeze the uppermost (plasma) layer into a separate bag  
30 pack which is aseptically (as with all connections)  
attached via a connecting tube to the main bag pack  
containing the separated blood. Simultaneously, the red  
blood cell layer is squeezed out of the main bag pack  
and into a separate bag pack attached to the bottom of  
35 the main bag pack.

- 51 -

Once the plasma is isolated, the pressing is momentarily halted and the tube connecting the plasma bag to the main blood reservoir bag is clamped shut. Similarly, once the red blood cells have been isolated into their  
5 respective bag pack, the red blood cell connection to the main bag pack is clamped. The white cells remain in the main bag pack.

10 The bag containing the white cell layer is detached and cells transferred aseptically into a fresh container and re-centrifuged under the aforementioned centrifugation conditions, although the conditions may be varied, so as to separate out any further plasma and red cells that may be contaminating the white cells into upper and  
15 lower layers respectively. The white cells are further separated, under aseptic conditions, from the remaining plasma and red cell layers.

20 A series of standard procedures (cell labelling and automatic FACS analysis, cell immuno-labelling and haemocytometer manual counting, flow cytometry after labelling etc.) are performed on a sub-sample to determine the total nucleated cell number obtained, the CD3<sup>+</sup> cell population, the CD4<sup>+</sup> and CD8<sup>+</sup> cell populations,  
25 the CD16/56<sup>+</sup> cell population, and the CD19<sup>+</sup> cell population in the sample. These were seen to vary in the different blood unit (450-500mls) samples between 0.35-1.5x10<sup>9</sup>, 0.2-0.9x10<sup>9</sup> and 0.1-0.7x10<sup>9</sup>, 0.06-0.32x10<sup>9</sup>, and 0.06-0.33x10<sup>9</sup> cells, respectively.

30 In this study, the cell samples obtained from each blood unit are frozen as described earlier. In short, the cell samples are mixed with an equal volume of autologous plasma containing 20% dimethylsulphoxide  
35 (DMSO) so as to provide a final sample for freezing with a concentration of about 10% DMSO. Alternatively, the cryopreservation solution, which was cooled to 4°C

- 52 -

before use, consisted of 20% DMSO and 40% autologous plasma in TC199 (Gibco, UK). Each sample is frozen slowly so as to lose about 1 degree Celsius every 1-2 minutes until well below the freezing point of water, 5 say, minus 40°C, and then 10°C per minute to minus 80°C or minus 120°C in a rate controlled freezer (e.g. Cryomed, New Baltimore, MD, USA). The frozen cell samples are then transferred to gas/liquid phase nitrogen/helium, or and/or liquid nitrogen followed by 10 gas and/or liquid helium for long term storage at approximately minus 196/269°C until required.

Cells are cryopreserved at various cell concentrations ranging from  $2 \times 10^7$  -  $8 \times 10^8$  cells per ml. No difference 15 in cell viability after thawing due to varying the cell concentration is seen.

Of the 50 healthy males sampled 34 have become HIV positive and are at various stages of disease 20 progression. A single infusion of between  $10^8$ - $1.5 \times 10^9$  cells is administered when a decline in CD4<sup>+</sup> cell counts is registered on two successive occasions of one month or more apart and when the CD4<sup>+</sup> count is below 300 cells per  $\mu$ l.

25 Before autologous infusion, the cells are rapidly thawed in a 37°C water bath near the patient. A volume of ACD-A (acid citrate dextrose formula A, Fenwall, Deerfield, IL, USA) equivalent to 20% of the thawed cell volume may 30 be added to the cells to prevent any cell clumping prior to infusion. Infusion is over a 5-10 minute period through a large bore intravenous catheter. Patients may be hydrated and medicated with diphenhydramine, mannitol, and hydrocortisone immediately before cell infusion. 35 Alternatively, they may be pre-medicated with an appropriate dose of promethazine hydrochloride.

- 53 -

Twenty seven of the now HIV positive patients are infused with autologous cells, which were cryopreserved when they were healthy individuals and not patients suffering from disease, with surprising immunological benefit. Despite the infusion of less than 1% of the entire lymphocyte population (which is  $5 \times 10^{11}$  in the adult human), of which only approximately 2% is in transit through the vascular compartment at any one time, there is a return of peripheral blood CD4<sup>+</sup> and CD8<sup>+</sup> cell numbers to the original pre-disease levels in all HIV positive patients that are infused. The basis for this is likely to be that the mature CD4<sup>+</sup> and CD8<sup>+</sup> cells are replicating in-vivo to replete the immune system. This seems to be the only explanation since, assuming normal patterns of lymphoid recirculation, the quantity of infused mature CD4<sup>+</sup> and CD8<sup>+</sup> cells should make imperceptible differences to the peripheral blood lymphocyte population following the first few hours/days of infusion. However, CD4<sup>+</sup> and CD8<sup>+</sup> peripheral blood cell populations remain at near normal levels over the six month follow-up study in all patients.

Example 9

A similar trial as outlined in Example 8 above is performed, however, leukapheresis is used as an alternative lymphocyte collection(s) process to whole blood sampling(s) for the healthy individuals involved in the trial as follows.

50 healthy adult males and 50 healthy adult females aged between 18-52 undergo 5-7 litres of blood volume leukapheresis at 40-60 mls blood per minute using a COBE Spectra (COBE BCT, Lakewood, CO, USA). During leukapherises, the individuals may be anticoagulated with acid dextrose citrate formula A (ACD-A) and heparin (5000U/500ml ACD-A) 20-40mls ACD-A may also be added to

- 54 -

the collection chamber to avoid the risk of cell clumping.

Excess plasma is removed from the collected cells by  
5 centrifugation in Baxter R7481 blood bag packs on a Beckman J6 centrifuge as described above. The total nucleated cell numbers collected ranged from between  $2.5 \times 10^{10}$ - $7 \times 10^{10}$ . 10-30 ml aliquots of cells at 0.1-  
10  $8.0 \times 10^8$  cells per ml are cryopreserved as described above without any loss of cell viability as a consequence of freezing cells at these different concentrations. All processes are performed aseptically.

Of the 100 healthy individuals sampled, 36 men and 28  
15 women have subsequently become infected with the HIV virus and soon present with CD4+ counts which have fallen.

As in Example 8 above autologous uninfected (because  
20 they are taken from the individual when free of disease) T-lymphocytes are grafted back to the host as a single infusion into the now infected patients - the cell numbers for grafting ranging from  $1 \times 10^7$ - $5 \times 10^9$ . Clear immunological benefit is seen in nearly 94% of patients.  
25 The apparent lack of immunological benefit in 4 of the patients correlates with infusions of less than  $5 \times 10^7$  cells. No difference is identified in beneficial effect between genders.

30 Example 10

Infusion of T-lymphocyte sub-populations:

In addition to the studies of infusions of mixed mature  
35 T-cell populations, studies are performed on purified T-cell populations. After sampling, the nucleated cell populations are separated using automated cell sorting

- 55 -

methods like flow cytometry, fluorescence activated cell sorting, Campath sorting or magnetic bead/monoclonal antibody sorting, or antibody binding lysis, either prior to cryopreservation or after thawing of  
5 cryopreserved cells.

The purified cell populations which have been physically separated from the mixed cell population, or whereby unwanted sub-populations have been lysed or inactivated  
10 so as to effectively purify sub-populations by leaving them as the only viable cells, are: the CD8<sup>+</sup> cytotoxic T-lymphocytes; the CD4<sup>+</sup> helper T-lymphocytes; CD16/56<sup>+</sup> natural killer T-lymphocyte cell population; and the CD19<sup>+</sup> B-lymphocytes.  
15

50 healthy adult males and 50 healthy adult females aged between 18-52 undergo 5-7 litres of blood volume leukapheresis at 40-60 mls blood per minute using a COBE Spectra (COBE BCT, Lakewood, CO, USA). During  
20 leukapheresis, the individuals may be anticoagulated with acid dextrose citrate formula A (ACD-A) and heparin (5000U/500ml ACD-A). 20-40mls ACD-A may also be added to the collection chamber to avoid the risk of cell clumping.  
25

Excess plasma is removed from the collected cells by centrifugation in Baxter R7481 blood bag packs on a Beckman J6 centrifuge as described above. The total nucleated cell numbers collected ranged from between  
30 2.5x10<sup>10</sup>-7x10<sup>10</sup>. The cell samples are subjected to separation procedures outlined above so as to provide purified sub-populations of CD8<sup>+</sup> cytotoxic T-lymphocytes; CD4<sup>+</sup> helper T-lymphocytes; CD16/56<sup>+</sup> natural killer T-lymphocyte cell population; and CD19<sup>+</sup> B-lymphocytes.  
35

33 men and 36 women of the 100 previously sampled healthy group have become HIV positive. 57 of the 69,

- 56 -

now patients, are shown to have depleted CD4<sup>+</sup> T-lymphocytes and when the CD4<sup>+</sup> T-lymphocyte count was reduced to 300 cells per  $\mu$ l blood the patients are infused with various lymphocyte populations or 5 combinations thereof.

Beneficial effects are shown with autologous infusion of purified sub-populations of CD8<sup>+</sup> cytotoxic T-lymphocytes; CD4<sup>+</sup> helper T-lymphocytes; CD16/56<sup>+</sup> natural killer T-lymphocytes; and CD19<sup>+</sup> B-lymphocyte cells as long as the 10 numbers of cells infused is approximately equal to or greater than those present in 100 mls of healthy whole blood, and more preferably those cells present in 200 mls of healthy whole blood or more.

15 The best results are obtained with CD8<sup>+</sup> cytotoxic T-lymphocytes or CD4<sup>+</sup> helper T-lymphocytes or combinations thereof. The next best results are seen with CD16/56<sup>+</sup> natural killer T-lymphocyte cells, or combinations of 20 CD16/56<sup>+</sup> natural killer T-lymphocyte cells with CD8<sup>+</sup> cytotoxic T-lymphocytes and/or CD4<sup>+</sup> helper T-lymphocytes. Beneficial effects in terms of decreasing patient viral load are seen when CD19<sup>+</sup> B-lymphocyte cells are infused but they did not raise CD8<sup>+</sup> cytotoxic T-lymphocytes 25 and/or CD4<sup>+</sup> helper T-lymphocytes counts in the peripheral blood of patients.

Example 11

30 This Example is identical to Example 10 above apart from the expansion of the different cell populations in culture prior to infusion. After thawing or prior to cryopreservation the selected cell populations are expanded in culture by incubation with a series of 35 haematopoietic growth factors and cytokines well known to the man skilled in the art. The factors used to induce cell expansion in the culture are: IFN- $\alpha$ , IFN- $\beta$ ,

- 57 -

IFN- $\gamma$ , IL-1 $\alpha$ , IL-1 $\beta$ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, and other cytokines. Also GM-CSF, M-CSF, G-CSF and LT. Individual cytokines and growth factors as well as 5 combinations are used to expand the cell populations in vitro or in-vivo prior to or at the time of infusion.

As in Example 10 above, the best results are obtained 10 with expanded populations of CD8 $^{+}$  cytotoxic T-lymphocytes or CD4 $^{+}$  helper T-lymphocytes or combinations thereof. The next best results are seen with expanded populations of CD16/56 $^{+}$  natural killer T-lymphocyte cells, or combinations of CD16/56 natural killer T-lymphocyte cells with CD8 $^{+}$  cytotoxic T-lymphocytes and/or CD4 $^{+}$  15 helper T-lymphocytes. Beneficial effects in terms of decreasing patient viral load are seen when expanded populations of CD19 $^{+}$  B-lymphocyte cells are infused but they did not raise CD8 $^{+}$  cytotoxic T-lymphocytes and/or CD4 $^{+}$  helper T-lymphocytes counts in the peripheral blood 20 of patients.

Example 12

This Example is as 11 above, but where the cell samples 25 are expanded also in the presence of HIV viral antigens so as to activate T and B-cells to recognise virus and virally infected cells and destroy them.

Beneficial results are obtained with this process.  
30

Example 13

A similar trial to 8 above is carried out on 50 healthy males. One unit (450-500 mls) of peripheral blood, 35 and/or multiple samplings at different times, is withdrawn from each of the 50 healthy males aged 47-62 years which is fractionated and white cells

- 58 -

cryopreserved under sterile conditions as described in Example 8.

In addition, cells are collected by leukapheresis from a  
5 further 50 healthy males aged between 38 and 60 as described in Example 9.

10 8 of the 100 healthy males are later diagnosed with early stage prostate cancer and autologous lymphocytes infused either without prior treatment, or after in vitro expansion in the presence of cytokines and/or prostate tumour antigens.

15 Beneficial effects are seen in that tumour metastasis is inhibited and tumour load decreased. Furthermore, autologous grafting of healthy cells after in vitro expansion as in Examples 11 and 12 above is of significant benefit where radiotherapy and/or chemotherapy has been used.

20

Example 14

A similar trial to 1 above is carried out on 50 healthy females. One unit (450-500 mls) of peripheral blood,  
25 and/or multiple samplings at different times, is withdrawn from each of the 50 healthy females aged 32-63 years which is fractionated and white cells cryopreserved under sterile conditions as described in Example 8.

30

In addition, cells are collected by leukapheresis from a further 50 healthy females aged between 31 and 54 as described in Example 9.

35 12 of the 100 healthy females are later diagnosed with early stage breast cancer and, in addition to their surgery and chemotherapy, autologous lymphocytes ( $1 \times 10^8$  -

- 59 -

$5 \times 10^{10}$ ) are infused either without prior treatment, or after in-vitro expansion in the presence of cytokines and/or breast tumour antigens.

- 5      Beneficial effects are seen in that tumour metastasis is inhibited and tumour load decreased. Furthermore, autologous grafting of healthy cells after in-vitro expansion as in Examples 11 and 12 above is of significant benefit where radiotherapy and/or  
10     chemotherapy has been used.

Example 15: Infection in aged patients

15     A similar trial to the above is carried out in healthy individuals. Fifty males and fifty females in good health, aged between 43 and 64 undergo leukapheresis of 5-10 litres of blood at 40-60 mls per minute, as described in Example 9.

- 20     The collected cells are further enriched by centrifugation (e.g. at 1200 g for 15 mins) in a Beckman J6 centrifuge, and removal of the excess plasma by aspiration. The total nucleated cell number ranges from 2.5-9.5 $\times 10^{10}$ ; 5-30ml aliquots of the collected cells at 0.5-2.0 $\times 10^9$  cells per ml are cryopreserved as described in Example 8 above, with no loss of cell viability resulting from the various cell concentrations used. All processes are performed aseptically.  
25  
30     Thirteen of the 100 individuals originally sampled in this study have become intractably ill due to bacterial or viral infection of the respiratory or gastrointestinal tract (age range 65-72), despite medical intervention with antibiotics and/or other drugs.  
35

Uninfected T-lymphocyte samples taken when the

- 60 -

individuals were free of disease, are reinfused autologously once the individual subsequently succumbs to the intractable microbial infection, the cell numbers being returned to the now infected individual ranging 5 from  $1 \times 10^8$ - $9.5 \times 10^9$ .

Clear medical benefit is obtained following such infusions, in that the infection is rapidly cleared. In addition, no reinfection is observed over the following 10 12 months, suggesting that immunity to disease has been reconferred or even conferred for the first time on the individual i.e. vaccination via autologous reinfusion of the individual's lymphocytes.

- 61 -

Claims 1 to 36 for all designated states except Europe,  
Australia, USA and Japan

Claims 37 to 67 for Europe, Australia, USA and Japan  
only

5

1. Use of a host cell population obtained from a non-diseased host organism for the preparation of a cell composition for use in subsequent autologous transplantation therapy of said host organism, wherein said non-diseased host organism is not in remission from the disease or disorder to be treated by said therapy.

10

2. A method of autologous transplantation therapy, said method comprising transplanting a host organism with a cell composition prepared from a host cell population obtained from said host organism when non-diseased, wherein said non-diseased host organism is not in remission from the disease or disorder to be treated by said therapy.

15

3. A composition comprising a host cell population obtained from a non-diseased host organism for use in subsequent autologous transplantation therapy of said host organism, wherein said non-diseased host organism is not in remission from the disease or disorder to be treated by said therapy.

20

4. A use, method or composition as claimed in any one of claims 1 to 3, wherein said host organism is a human.

25

5. A use, method or composition as claimed in any one of claims 1 to 4, wherein said host organism is juvenile, adolescent or adult.

30

6. A use, method or composition as claimed in any one of claims 1 to 5, wherein the immune system of said host organism is mature.

- 62 -

7. A use, method or composition as claimed in any one of claims 1 to 6, wherein the immune system of said host organism is uncompromised.
- 5 8. A use, method or composition as claimed in any one of claims 1 to 7, wherein said host cell population comprises a stem cell or progenitor cell.
- 10 9. A use, method or composition as claimed in any one of claims 1 to 7, wherein said host cell population comprises a mature cell.
- 15 10. A use, method or composition as claimed in any one of claims 1 to 9, wherein said host cell population is derived from haemopoietic tissue or marrow stroma.
11. A use, method or composition as claimed in claim 8, wherein said host cell population is derived from neural tissue.
- 20 12. A use, method or composition as claimed in any one of claims 1 to 10, wherein said host cell population comprises a T-lymphocyte cell.
- 25 13. A use, method or composition as claimed in claim 12, wherein said T-lymphocyte cell is a mature T-lymphocyte.
- 30 14. A use, method or composition as claimed in any one of claims 1 to 13, wherein said therapy is therapy of a chronic condition.
- 35 15. A use, method or composition as claimed in any one of claims 1 to 13, wherein said therapy is cancer therapy.

- 63 -

16. A use, method or composition as claimed in any one of claims 1 to 14, wherein said therapy is neurodegenerative disease therapy.
- 5 17. A use, method or composition as claimed in any one of claims 1 to 14, wherein said therapy is for osteoporosis or osteoarthritis.
- 10 18. A use, method or composition as claimed in any one of claims 1 to 14, wherein said therapy is for HIV infection or AIDS.
- 15 19. A use, method or composition as claimed in any one of claims 1 to 18, wherein said host cell population is maintained in a state of dormancy.
- 20 20. A use, method or composition as claimed in any one of claims 1 to 19, wherein said host cell population comprises a genetically modified cell.
- 25 21. A use, method or composition as claimed in any one of claims 1 to 20 wherein said host cell population has been treated with or further comprises a stimulatory molecule.
22. A use, method or composition as claimed in any one of claims 1 to 21, wherein said host cell population comprises cultured cells.
- 30 23. A use, method or composition as claimed in any one of claims 1 to 7, 9 or 12 to 22, wherein said host cell population comprises or is derived from peripheral blood.
- 35 24. A use, method or composition as claimed in any one of claims 1 to 7, 9 or 12 to 22 or claim 24, wherein said cell population comprises at least  $0.1 \times 10^6$  mature T-

- 64 -

lymphocytes.

25. A use, method or composition as claimed in claim  
24, wherein said cell population comprises from  $0.1 \times 10^8$   
5 to  $1 \times 10^{10}$  mature T-lymphocytes.

26. A use, method or composition as claimed in claim  
24, wherein said cell population comprises at least  $1 \times 10^9$   
mature T-lymphocytes.

10

27. A use, method or composition as claimed in claim  
24, 25 or 26, wherein said T-lymphocytes are CD3<sup>+</sup>.

15

28. A use, method or composition as claimed in claim  
27, wherein said T-lymphocytes are CD3<sup>+</sup> and CD4<sup>+</sup>.

29. A use, method or composition as claimed in any one  
of claims 24 to 28, wherein said T-lymphocytes are  
CD16/56<sup>+</sup>.

20

30. A use, method or composition as claimed in any one  
of claims 13 to 29 wherein said cell population further  
comprises mature B-cells.

25

31. A use, method or composition as claimed in claim  
30, wherein said cell population comprises at least  $10^7$   
mature B-cells.

30

32. A use, method or composition as claimed in claim  
30, wherein said cell population comprises at least  $10^9$   
mature B-cells.

35

33. A use, method or composition as claimed in claim  
30, wherein said cell population comprises from  $5 \times 10^7$  to  
 $10^{10}$  mature B-cells.

- 65 -

34. A method of making and/or maintaining cells dormant, said method comprising freezing said cells to a temperature at or below -269°C.
- 5      35. A method as claimed in claim 34, wherein said cells comprise a host cell population as defined in any one of claims 23 to 33.
- 10     36. A dormant cell population obtained by the method of claim 34 or 35.

- 66 -

37. Use of a host cell population obtained from a non-diseased host organism for the preparation of a cell composition for use in subsequent autologous transplantation therapy of said host organism, wherein  
5 said host cell population comprises at least  $0.1 \times 10^8$  mature T-lymphocytes.
38. A method of autologous transplantation therapy, said method comprising transplanting a host organism  
10 with a cell composition prepared from a host cell population obtained from said host organism when non-diseased, wherein said host cell population comprises at least  $0.1 \times 10^8$  mature T-lymphocytes.
- 15 39. A composition comprising a host cell population obtained from a non-diseased host organism for use in subsequent autologous transplantation therapy of said host organism, wherein said host cell population comprises at least  $0.1 \times 10^8$  mature T-lymphocytes.
- 20 40. A use, method or composition as claimed in any one of claims 37 to 39, wherein said cell population comprises from  $0.1 \times 10^8$  to  $1 \times 10^{10}$  mature T-lymphocytes.
- 25 41. A use, method or composition as claimed in any one of claims 37 to 39, wherein said cell population comprises at least  $1 \times 10^9$  mature T-lymphocytes.
- 30 42. A use, method or composition as claimed in claim 40 or 41, wherein said T-lymphocytes are CD3<sup>+</sup>.
43. A use, method or composition as claimed in claim 42, wherein said T-lymphocytes are CD3<sup>+</sup> and CD4<sup>+</sup>.

- 67 -

44. A use, method or composition as claimed in any one of claims 37 to 43, wherein said T-lymphocytes are CD16/56<sup>+</sup>.
- 5 45. A use, method or composition as claimed in any one of claims 40 to 44 wherein said cell population further comprises mature B-cells.
- 10 46. A use, method or composition as claimed in claim 45, wherein said cell population comprises at least 10<sup>7</sup> mature B-cells.
- 15 47. A use, method or composition as claimed in claim 45, wherein said cell population comprises at least 10<sup>9</sup> mature B-cells.
- 20 48. A use, method or composition as claimed in claim 45, wherein said cell population comprises from 5x10<sup>7</sup> to 10<sup>10</sup> mature B-cells.
49. A use, method or composition as claimed in any one of claims 37 to 48, wherein said host organism is a human.
- 25 50. A use, method or composition as claimed in any one of claims 37 to 49, wherein said host organism is juvenile, adolescent or adult.
51. A use, method or composition as claimed in any one of claims 37 to 50, wherein the immune system of said host organism is mature.
- 30 35 52. A use, method or composition as claimed in any one of claims 37 to 51, wherein the immune system of said host organism is uncompromised.

- 68 -

53. A use, method or composition as claimed in any one  
of claims 37 to 52, wherein said host cell population  
further comprises a stem cell or progenitor cell.
- 5 54. A use, method or composition as claimed in any one  
of claims 37 to 53, wherein said host cell population is  
derived from haemopoietic tissue or marrow stroma.
- 10 55. A use, method or composition as claimed in claim  
54, wherein said host cell population is derived from  
neural tissue.
- 15 56. A use, method or composition as claimed in any one  
of claims 37 to 55, wherein said host cell population  
comprises or is derived from peripheral blood.
- 20 57. A use, method or composition as claimed in any one  
of claims 37 to 56, wherein said therapy is therapy of a  
chronic condition.
58. A use, method or composition as claimed in any one  
of claims 37 to 56, wherein said therapy is cancer  
therapy.
- 25 59. A use, method or composition as claimed in any one  
of claims 37 to 57, wherein said therapy is  
neurodegenerative disease therapy.
- 30 60. A use, method or composition as claimed in any one  
of claims 37 to 57, wherein said therapy is for  
osteoporosis or osteoarthritis.
- 35 61. A use, method or composition as claimed in any one  
of claims 37 to 57, wherein said therapy is for HIV  
infection or AIDS.

- 69 -

62. A use, method or composition as claimed in any one of claims 37 to 61, wherein said host cell population is maintained in a state of dormancy.

5 63. A use, method or composition as claimed in any one of claims 37 to 62, wherein said host cell population comprises a genetically modified cell.

10 64. A use, method or composition as claimed in any one of claims 37 to 62 wherein said host cell population has been treated with or further comprises a stimulatory molecule.

15 65. A use, method or composition as claimed in any one of claims 37 to 64, wherein said host cell population comprises cultured cells.


20 66. A method of making and/or maintaining cells dormant, said method comprising freezing said cells to a temperature at or below -269°C, wherein said cells comprise a host cell population as defined in any one of claims 37 to 56 or 62 to 65.

25 67. A dormant cell population obtained by the method of claim 66.

1/3

Fig. 1


**Protection from effects of X-irradiation using cryopreserved autologous white cells**



2/3

Fig.2


**Presence of hygromycin resistance gene in rats with autologous grafts of genetically engineered T-lymphocytes**



3/3

Fig.3

**Presence of hygromycin resistance gene in rats with autologous grafts of T-lymphocytes genetically engineered after cryopreservation**



## INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/GB 00/01873

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C12N5/06

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 39427 A (UNIV MASSACHUSETTS) 11 September 1998 (1998-09-11)  Invention 1 page 26, line 8 - line 17 page 2, line 35 -page 3, line 9 page 4, line 26 - line 27; claims 33,34	1-10, 12-15, 17, 19-33, 37-54, 56-58, 60,62-65
Y	---	11, 16-18, 35,36, 55, 59-61, 66,67
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed Invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

16 February 2001

Date of mailing of the international search report

22/02/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Sprinks, M

## INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/GB 00/01873

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 750 376 A (REYNOLDS BRENT ET AL) 12 May 1998 (1998-05-12) Invention 1 column 1, line 39 - line 57 ----	11,16, 55,59
Y	WO 97 30157 A (INCYTE PHARMA INC ;COCKS BENJAMIN GRAEME (US); AU YOUNG JANICE (US) 21 August 1997 (1997-08-21) Invention 1 page 6, line 4 - line 8 ----	18,61
X	WO 94 16715 A (CELLCARE INC) 4 August 1994 (1994-08-04)	1-10, 12-15, 18-33, 37-54, 56-58, 61-65
	Invention 2 page 10, line 29 -page 12, line 6 page 14, line 15 -page 15, line 20 page 31, line 3 - line 20	
Y	----	11,16, 35,36, 55,59, 60,66,67
X	EP 0 668 013 A (NIPPON TELEGRAPH & TELEPHONE) 23 August 1995 (1995-08-23)	1-9, 12-15, 18-53, 56-58, 61-67
	Invention 2 page 2, line 12 - line 15	
	Invention 3 page 2, line 16 - line 20	
Y	----	17,35, 36,60, 66,67
A	WO 95 06247 A (VIVIER ERIC ;DANA FARBER CANCER INST INC (US); ANDERSON PAUL (US)) 2 March 1995 (1995-03-02) abstract ----	29,44

## INTERNATIONAL SEARCH REPORT

Information on patent family members

In	International Application No
PCT/GB 00/01873	

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9839427	A	11-09-1998	AU	6346898 A	22-09-1998
US 5750376	A	12-05-1998	US	6071889 A	06-06-2000
			US	5981165 A	09-11-1999
			US	5980885 A	09-11-1999
			US	5851832 A	22-12-1998
			AU	697894 B	22-10-1998
			AU	8056194 A	29-05-1995
			CA	2175992 A	18-05-1995
			WO	9513364 A	18-05-1995
			CN	1141058 A	22-01-1997
			EP	0728194 A	28-08-1996
			FI	961855 A	04-06-1996
			JP	9507747 T	12-08-1997
			NO	961859 A	03-07-1996
			AU	714837 B	13-01-2000
			AU	3515295 A	09-04-1996
			CA	2200709 A	28-03-1996
			WO	9609543 A	28-03-1996
			EP	0783693 A	16-07-1997
			FI	971168 A	20-03-1997
			JP	10505754 T	09-06-1998
			NO	971245 A	18-03-1997
			AU	716811 B	09-03-2000
			AU	3836795 A	06-06-1996
			WO	9615226 A	23-05-1996
			CN	1170435 A	14-01-1998
			EP	0792350 A	03-09-1997
			FI	971956 A	04-07-1997
			JP	10509592 T	22-09-1998
			NO	972171 A	07-07-1997
			AU	665012 B	14-12-1995
			AU	2242592 A	11-02-1993
			CA	2113118 A	21-01-1993
			WO	9301275 A	21-01-1993
			EP	0594669 A	04-05-1994
			FI	935929 A	02-02-1994
			JP	6509225 T	20-10-1994
			NO	940056 A	03-03-1994
			WO	9416718 A	04-08-1994
			AU	683023 B	30-10-1997
			AU	5147493 A	09-05-1994
			CA	2147162 A	28-04-1994
			WO	9409119 A	28-04-1994
			EP	0664832 A	02-08-1995
			FI	951677 A	07-04-1995
			JP	8502172 T	12-03-1996
			NO	951378 A	07-04-1995
			AU	703729 B	01-04-1999
			AU	4924197 A	12-03-1998
			AU	5367694 A	24-05-1994
WO 9730157	A	21-08-1997	US	5866332 A	02-02-1999
			AU	1960797 A	02-09-1997
			CA	2246578 A	21-08-1997
			EP	0894137 A	03-02-1999
			JP	2000517163 T	26-12-2000

## INTERNATIONAL SEARCH REPORT

Information on patent family members

In	ional Application No
PCT/GB 00/01873	

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9416715	A 04-08-1994	AU 6167394	A	15-08-1994	
		CA 2154787	A	04-08-1994	
		EP 0752867	A	15-01-1997	
		JP 8511935	T	17-12-1996	
EP 0668013	A 23-08-1995	JP 8109136	A	30-04-1996	
		US 5656498	A	12-08-1997	
WO 9506247	A 02-03-1995	EP 0714510	A	05-06-1996	
		JP 9502089	T	04-03-1997	
		US 5786160	A	28-07-1998	